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Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest 5-year survival rates amongst 
solid tumors. As early detection of PDAC is unusual and typically incidental, most patients 
present with locally advanced and metastatic disease where effective therapeutic strategies 
remain a significant unmet need. Specifically, surrogate biomarkers for tumor monitoring of 
PDAC may lead to improved elucidation of clinical actionability and prognostic potential. On the 
other hand, tumor tissue is rarely sampled in patients presenting with de novo or recurrent 
metastatic PDAC, apart from a fine needle aspiration or a core needle biopsy performed for 
diagnosis. This precludes the opportunity for elucidating molecular underpinnings of cancer 
recurrence, chemoresistance, and therapeutic decision-making in advanced disease patients 
over the course of their therapy. For this reason, we aim to use so called “liquid biopsies” in the 
form of circulating nucleic acids and exosomes as a strategy that is amenable to longitudinal, 
relatively non-invasive sampling. Circulating tumor DNA and circulating exosomes contain 
genetic cargo representative of the neoplastic cells from which they are released and can serve 
as a reliable surrogate of the patient’s tumor DNA, enabling a new way of interrogating cancers. 
We demonstrate that serial quantitative measurements of these tumor nucleic acid sources in 
circulation can provide clinically relevant predictive and prognostic information in pancreatic 
cancer patients, including anticipation of impending disease progression and putative 
mechanisms of resistance to ongoing therapy. We also describe our ability to specifically capture 
tumor material in circulation following a comprehensive characterization of the pancreatic cancer 
exosomal “surfaceome”. By leveraging an immune-capture approach paired with ultrasensitive 
molecular barcoding techniques, we are able to increase our sensitivity of detection of rare 
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molecules in circulation that are derived from the tumor. Ultimately, this has implications for 
stratification of patients into therapeutic “buckets” through a personalized approach that may lead 
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Chapter 1 – Introduction  
Pancreatic Cancer  
Although rare (2% of cancer cases), pancreatic ductal adenocarcinoma (PDAC) is the 
fourth leading cause of cancer-related deaths in this country. In contrast to the decline of cancer 
related deaths from other malignancies, the alarming rise in incidence of PDAC is projected to 
make it the second leading cause of cancer related death by 2030 (1). The relatively equal 
incidence and mortality rates in PDAC have led to its dire prognosis, with a 5-year survival rate 
of only 4% (2). The lethality of PDAC is attributed in part to the lack of early detection, with the 
majority of patients (~85%) presenting with locally advanced or metastatic disease. Diagnosis at 
these late stages is due to the absence of specific symptoms and clinical findings due to its 
retroperitoneal location, and a lack of serological tests that are sufficiently sensitive and specific. 
In addition, the therapeutic landscape of PDAC is limited, with Gemcitabine and FOLFIRINOX 
(folinic acid, fluorouracil, irinotecan, and oxaliplatin) being the two main regimens with low overall 
response rates.  The main oncogenic driver mutation, observed in >90% of PDAC, KRAS (v-
Kiras2 Kirsten rat sarcoma viral oncogene homolog) has also compounded its poor survival rate 
due to its “undruggability”; although chemotherapeutic strategies may exist in certain targetable 
cases as discussed below.  
Advances in next generation sequencing (NGS) technologies have allowed for a detailed 
insight into the genomic landscape of PDAC, in order to better understand how molecular 
alterations contribute to disease initiation and progression. In particular, dissecting the molecular 
events involved in the progression of PDAC from pancreatic intraepithelial neoplasia (PanINs) 
lesions to invasive carcinoma, are being achieved with possible implications to targeted 
therapeutic approaches.  
Multi-step progression of PDAC 
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 The progression of PDAC from a normal cell to an invasive adenocarcinoma involves the 
accumulation of inherited and/or acquired mutations throughout the span of up to approximately 
20 years (3). This highlights the importance of exploiting this window of progression to develop 
new screening methods to provide curative surgical approaches. This progression involves the 
evolution of histologically recognized precursor lesions known as pancreatic intraepithelial 
neoplasias (PanINs). As of date of this publication, the categorization of PanIN is divided into low 
grade (PanIN-1A and 1B), intermediate (PanIN-2), and high-grade PanIN-3)(4), although there 
is an emerging consensus in the clinical research community to move to a simplified two-tier 
classification of “low” grade (PanIn-1 and -2) and “high” grade PanINs (PanIN-3).  This is based 
on observations that, while PanIN-1 and-2 lesions can be found even in the absence of cancer, 
PanIN-3 is almost never found without concomitant invasive neoplasia.  Genetic alterations can 
be grouped into those that arise in precursor lesions and are usually, albeit not always, found in 
the concomitant PDAC, versus those that arise during subclonal evolution of the infiltrating 
carcinoma resulting in genetic heterogeneity. 
One of the earliest genetic events involved in PDAC pathogenesis is an activating point 
mutation in the KRAS oncogene, an oncogenic driver mutation found in more than 90% of all 
PDACs. Subsequent genetic aberrations include inactivation of tumor suppressor genes 
including CDKN2A, TP53, and SMAD4, which encode for p16INK4A, p53, and Smad4, 
respectively, and contribute to the histological evolution of these precursor lesions.  Together, 
these four alterations comprise the “big four” in PDAC, although many other recurrent somatic 
mutations are found in lower frequencies (5-10%) of cases, including those that afflict particular 
functional pathways in the cancer cell, such as DNA damage repair or chromatin regulation.   
Among the population of noninvasive precursor lesions, it is also important to recognize 
intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs).  
Although histologically distinct from the microscopic PanIN lesions, these cystic precursor lesions 
share similar diver mutations including point mutations in the KRAS oncogene(5), and 
inactivating mutations in p53 and p16, with SMAD4 loss typically not being found in IPMNs (6, 
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7). Among the unique drivers found in both IPMNs and MCNs, are inactivating mutations in 
RNF43, encoding for an ubiquitin ligase that has a role in WNT signaling inhibition(5). IPMNs 
also contain point mutations in the GNAS gene, which result in constitutively active guanine 





Under physiological conditions, activation of Ras protein is induced through growth factor 
receptor signaling, which promotes Ras activity through transitory binding to GTP. This results in 
the interaction of Ras with a variety of downstream effectors that govern proliferation, cell 
division, survival, and gene expression such as the RAF-mitogen-activated protein kinase and 
phosphoinositide 3-kinase pathways (9). Through an intrinsic GTPase mechanism and GTPase-
activating proteins, Ras can then hydrolyze GTP to GDP to inactivate itself. It is this intrinsic 
GTPase activity that is altered in the activating point mutation of KRAS, which results in an 
inability to hydrolyze GTP allowing for a constitutively active protein that no longer relies on 
external stimuli.  The most common “hotspot” mutation in the KRAS oncogene occurs at codon 
12, followed by codon 13, and less frequently codon 61; emerging genomic data suggests that 
the specific codon involved might have an impact on disease prognosis, underscoring differences 
in Ras function (10, 11).  
 
Telomere shortening 
Telomeres are repetitive nucleoprotein complexes found at the end chromosomes that 
have a role in genomic stability by protecting against chromosomal degradation and chromosome 
end fusion.  In PDAC, shortened telomeres lengths that potentially lead to chromosomal 
abnormalities can be detected in early lesions such as IPMNs and nearly universally in all PanINs 
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(12). Genomic instability of this kind will typically lead to cell death unless cells are able to 
inactivate tumor suppressor mechanisms as described below.  
 
CDKN2A 
The most commonly mutated tumor suppressor in PDAC (~95%) is an inactivation of 
cyclin-dependent kinase inhibitor 2A gene (CDKN2A), encoding for the cell cycle checkpoint 
protein, p16INK4A(13). Inactivation of CDKN2A in PDAC can occur via several different 
mechanisms, including mutation, genomic deletions, and promoter hypermethylation resulting in 
epigenetic silencing.  (14).  The encoded protein p16INK4A functions as a cyclin-dependent kinase 
inhibitor, specifically of CDK4 and CDK6 thereby preventing the phosphorylation of the 
retinoblastoma protein and blocking G1-S transition(15). Loss of this protein thus results in 
unregulated cell cycle transition.  
 
TP53 
Aberrations of TP53, which encodes for p53, are typically a later event in the multi-
progression of PDAC, often arising in PanIN-3 lesions, and is mutated in up to 70% of tumors(16). 
As the master guardian of the genome, p53 is involved in cell cycle arrest, DNA repair, blocking 
of angiogenesis, and induction of apoptosis in response to DNA damage or environmental 
stressors.  Loss of this protein allows for DNA damage and external stressors to go unchecked, 
thereby promoting genomic instability and aberrant proliferation.  
 
SMAD4 
SMAD4 (DPC4, SMAD family member 4 gene), which encodes for the Smad4 protein, is 
inactivated in approximately 50% of PDACs as a late event in its progression (PanIN-3 – 
Carcinoma) (17).  As a downstream effector of transforming growth factor-β (TGF- β), loss of 
SMAD4 activity leads to tumor promotion by relieving the growth inhibitory effect of TGF- β 
signaling (18).  
  6 
 
Clinical Relevance of Core PDAC Mutations 
Although pancreatic cancers have been shown to harbor an average of 63 genetic 
mutations, the genomic landscape of PDAC is faithfully represented by these four genomic 
mutations (KRAS, CDKN2A, TP53, and SMAD4)(10). The high degree of mutational 
concordance at these four loci between primary and metastatic sites of individual cancers (19) 
suggests these are so-called founder mutations. This describes a mutation present in all samples 
from a single patient, thus sharing a common ancestor, which likely originated during PanIN 
progression (3, 12).  Of note, PDACs continue to accumulate genetic alterations through 
subclonal evolution throughout their natural history, the vast majority of which are so-called 
“passenger” mutations that have little functional impact on progression, while a minor fraction are 
so-called “progressor” mutations, and do have a deleterious consequence on disease 
progression.  In any case, a variable combination of the “big four” is altered in most PDAC cases, 
with nearly all cancers showing at least KRAS mutations in conjunction with one or more of the 
three tumor suppressors. Yachida et. al. describe correlations of the status of these 4 genes to 
disease progression, metastatic failure, and overall survival, with patients with 3-4 of these 
mutated driver genes demonstrating worse overall survival (19). When looking at the genes 
individually, there is no significant difference in outcome in patients with KRAS and CDKN2A 
mutations, but TP53 and SMAD4 mutations were evidently associated with widespread 
metastatic disease and worse clinical outcomes (20, 21).  In particular, SMAD4 status in PDAC 
(measured using immunohistochemical expression for the Smad4 protein) is being used to 
provide guidance towards tailoring treatment with systemic chemotherapy, as patients with 
Smad4-null tumors are most likely to develop widely metastatic disease. (22).  
 
Germline Variants 
With estimates of 10% of PDAC patients having a family history of the disease, elucidation 
of the PDAC genome has also contributed towards risk assessment and early detection in the 
  7 
context of familial pancreatic cancers(23, 24). Among hereditary pancreatic cancer susceptibility 
genes, STK11/LKB1, associated with Peutz-Jegher syndrome, is correlated with one of the 
highest risks of familial pancreatic cancers with approximately 132x relative lifetime risk (25).  
PRSS1 and SPINK1 germline mutations are seen hereditary pancreatitis families with a 50-80x 
relative lifetime risk, or 30-44% risk, of developing PDAC (26-28). P16/CDKN2A germline 
mutations, associated with familial atypical multiple mole melanoma syndrome (FAMMM), entails 
a 38x (17% lifetime risk) increased risk of developing PDAC (29).  Additional germline variants 
associated with increased PDAC risk are clustered into defects of DNA repair pathways. This 
includes members of the Fanconi anemia pathway such as FANC-C, FANC-G, and PALB2, 
whose encoded proteins interact with that of BRCA2, and are associated to young onset 
pancreatic cancer (30). BRCA1/BRCA2 mutations, which are associated with familial breast and 
ovarian cancers, have a 3.5-10x estimated relative risk (31-33).  Lynch syndrome, caused by 
mutations in DNA mismatch repair (MMR) genes, MLH1, MSH2, MSH6 or PMS2, have an 
estimated 3.68% lifetime risk (34). Patients with ATM (Ataxia telangiectasia mutated) germline 
mutations have also demonstrated a predisposition for PDAC (35). Further elucidation of 
additional genes associated with familial PDAC may have implications for risk assessment and 
surveillance in affected family members.  Detection of these germline mutations in patients is 
also important in the context of therapy as a way to exploit synthetic lethal interactions in the 
case of DNA repair pathways as described below. 
 
Core Signaling pathways in pancreatic cancer 
Large scale sequencing efforts have uncovered novel mutated genes in PDAC, as well as 
revealing multiple core signaling pathways that are affected throughout its carcinogenesis. In 
2008, Jones et. al. performed polymerase chain reaction (PCR)-based exome sequencing of 
primary and metastatic tumors (10).  Their data supported the role of the 4 main genetic drivers 
in pancreatic cancer, KRAS, CDKN2A, TP53, SMAD4, and identified genetic alterations in many 
other critical pathways recognized as “hallmarks of cancer”, at least some of which appear to 
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have a prognostic influence in subsequent studies (11, 36). The core “hallmarks of pancreatic 
cancer” pathways that appear to be targeted in PDAC are highlighted in Table 1 with some salient 
examples of genes mutated in each pathway.   
Table 1: Core hallmarks of pancreatic cancer pathways  
 
Apoptosis              CASP10, VCP, CAD 
DNA damage control  TP53, RANBP2, EP300 
Regulation of G1/S phase 
transition  
CDKN2A, FBXW7, APC2 
Hedgehog signaling GLI1, GLI3, BMPR2 
Homophilic cell adhesion CDH1, CDH2, CDH10, PCDH15 
Integrin signaling ITGA4, ITHA9, LAMA1, FN1 
C-Jun N-terminal kinase 
signaling 
MAP4K3, TNF, ATF2 
KRAS signaling KRAS, MAP2K4, RASGRP3 
Regulation of invasion ADAM11, ADAM12, DPP6, MEP1A 
Small GTPase-dependent  PLXNB1, AGHGEF7, PLCB3, RP1 
TGF-B signaling SMAD4, SMAD3, TGFBR2, BMPR2 
Wnt/Notch signaling MYC, GATA6, WNT9A, MAP2, TCF4 
 
The altered genes in these respective pathways varied among separate patient tumors, such 
as the TGF-B pathway being altered by a SMAD4 mutation in one patient versus a BMPR2 
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mutation in another, but the pathway in itself is often altered among samples.  With this new 
global view of the PDAC genome as a set of a specific and limited number of pathways involved, 
we can begin to simplify the genetic heterogeneity that is intrinsic to these tumors and develop 
strategies to target the physiological effects of the mutations rater than the specific mutations 
themselves. By targeting key nodes involved in these pathways, such as the impaired ability to 
repair DNA, or altered cell cycle control, we may be able to circumvent the inevitable resistance 
that these tumors develop following targeted gene therapies.  
 In 2012 Biankin et. al. performed next generation sequencing of whole exomes and  copy 
number analysis of primary resected PDAC from 142 patients, under the umbrella of the 
International Cancer Genome Consortium (ICGC) (37). This study reaffirmed the core signaling 
pathways identified by Jones et. al. (10), and also discovered novel mutated genes in these core 
signaling pathways including those involved in DNA damage repair (ATM), which is also shown 
to have a role in familial PDAC. Novel gene signatures were also identified in axon guidance 
pathway genes (SLIT/ROBO signaling) which are known to have a role in neuronal migration and 
positioning during embryogenesis with potential implications in cancer cell survival, growth, 
invasion and angiogenesis (38).  Deregulation of these axon guidance genes was shown to have 
a role in tumor initiation and progression in the context of PDAC.  Particularly, low ROBO2 or 
high ROBO3 expression was seen to be associated to poor patient survival. High expression of 
Semaphorin signaling molecules, specifically SEMA3A and PLXNA1 were also determined to be 
associated with poor patient survival. The ICGC team’s methodology provided them the 
opportunity to identify potential novel drivers of pancreatic cancer, and new nodal signaling 
targets involving axon guidance, where therapeutics are currently developed for neuronal 
regeneration after injury (39). Again, we see the importance of developing therapeutics based on 
molecular phenotypes as further elucidation of genetic heterogeneity provides a cumbersome 
picture of pancreatic cancer.  
In 2015, the next iteration of the ICGC PDAC dataset was published by Waddell et. al, who 
performed whole genome sequencing and copy number variation analysis of 100 PDACs, and 
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demonstrated chromosomal rearrangements that led to genetic aberrations(40). These structural 
rearrangements led to gene deletions, amplifications and fusions that are associated with driving 
carcinogenesis while presenting opportunities for clinical actionability and biomarkers of 
therapeutic response for platinum based chemotherapies.  This led to the classification of PDACs 
into 4 subtypes based on structural rearrangement profiles (Table 2). 
 
Table 2: PDAC structural rearrangements profiles 
 
Stable  Small number of structural rearrangements (<50) with 
defects in cell cycle characterized by aneuploidy. 
Locally 
rearranged  
Presence of intra-chromosomal rearrangements 
classified as complex: leading to chromothripsis or 
breakage-fusion-bridge cycles; or focal copy number 
gains in genes such as KRAS, SOX9, GATA6 and 
potential therapeutic targets like ERBB2, MET, CDK6, 
PIK3CA, and PIK3R3. 
Scattered  Chromosomal aberrations due to structural 
rearrangements (50-200) throughout the genome.  
Unstable  Widespread structural rearrangements (>200) with 
genomic instability pointing towards somatic or germline 
deleterious mutations in DNA maintenance pathways 
(e.g. BRCA1, BRCA2, and PALB2) which suggest 
sensitivity to DNA damaging agents. A subset of these 
patients who were treated with platinum based therapy at 
tumor recurrence demonstrated robust or exceptional 
responses. 
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In addition to the classic “big four” and alterations in genes whose products are involved in 
DNA maintenance, the Waddell et al study highlighted the emerging importance of chromatin 
regulatory genes in the pathogenesis of PDAC.  In particular, mutations of genes whose encoded 
proteins are involved in histone modification (MLL2, MLL3, KDM6A) and SWI/SNF genes that 
regulate how DNA is packaged in nucleosomes. (ARID1A, ARID2) emerged as a family of driver 
genes with unequivocal significance in PDAC.  A recent whole exome study of resected PDAC 
patients by Sausen et. al. found strikingly favorable impact of harboring MLL2 or MLL3 mutations 
in the corresponding tumor, although the functional basis for this observation is still being 
elucidated (36).  Inactivation of other tumor suppressors such as ROBO1, ROBO2, SLIT2, and 
RNF43 also demonstrate the role of aberrant WNT signaling in PDAC, as well as the potential 
for sensitivity that these mutations may confer to WNT inhibitors (41).  
Overall, the recent series of exome studies in PDAC have suggested that a major mechanism 
of genomic instability and damage in pancreatic cancer involves structural variations and their 
potential clinical relevance. This supports the role of platinum based regimens such as 
FOLFIRINOX in a subgroup of patients that are both able to tolerate the regimen and contain a 
signature of impaired DNA maintenance pathways due to an unstable structural rearrangement 
phenotype within their tumors. It may also provide a model for patient stratification for PARP-1 
inhibitor therapy as current clinical trials are predominantly restricted to patient populations with 
BRCA1 and BRCA2 germline defects. This new model also allows for a surrogate measure of 
defects in DNA maintenance where there may be a larger population that may benefit from such 
therapies who have non-BRCA pathway gene mutations, but whose unstable tumor subtype 
suggests sensitivity to DNA damaging agents.  
More recently, Bailey et. al. have used exome and RNA profiling on 450 PDAC samples in 
the ICGC cohort to define 4 subtypes of PDAC based on differential gene expression signatures 
with distinct biological underpinnings: Squamous, Pancreatic Progenitor, ADEX (aberrantly 
differentiated endocrine exocrine) and Immunogenic (unpublished data, Biankin et al personal 
communication).  While each of these molecular subtypes is enriched in a particular histological 
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variant (for example, the nom de plume for Squamous subtype arising from its enrichment of 
adenosquamous carcinomas in this subset), the intent of this expression signature is to tease 
out biological distinctions that might underlie PDACs that look identical at the morphological level.  
Not surprisingly, as is being increasingly noted across pan-cancer profiling datasets, there exists 
striking molecular similarities between subtypes across cancer types than within subtypes in a 
single cancer.  Thus, the squamous subtype of PDAC has greater similarities to the so-called 
basal type cancers observed in head and neck and triple negative breast cancers (characterized 
by a overriding p63-driven signature) than to the other three PDAC subtypes.   
Among clinical actionability in these subtypes, MYC amplifications have been found to be 
associated to the adenosquamous subtype with a correlation to poor survival (11). Also, 
appreciable differences in roles of the immune system can be identified, which may lead to 
exploiting immunotherapeutic strategies. In the case of the squamous subtype, a loss of cytotoxic 
T cells was associated with an increase in Toll-like receptors, CD4+ T cells and macrophages, 
as well as high expression of CTLA4 and PD1 immunosuppressive pathways. Stratification 
based on these subtypes may thus assist in clinical trial patient selection for therapeutics such 
as PD1 and CTLA4 checkpoint inhibitors to decipher their potential role in this disease.  
Many of these recent global sequencing efforts provide a biomarker-based approach in order 
to identify surrogates for prognostic and therapeutic stratification. As most of the sequencing data 
provided was performed on patients with surgically resectable primary tumors versus those 
undergoing recurrence or falling into the locally advanced or metastatic category, the complete 
picture of PDAC remains limited to a small subset of patients (~15%). Still, these efforts provide 
proof of concept on how measures of aberrant molecular mechanisms may inform clinical 
actionaibility using next generation sequencing techniques.  
New promising strategies involving liquid biopsies are being developed as noninvasive 
methods of disease detection and monitoring (42, 43). Specifically, through the use of circulating 
tumor DNA (ctDNA) that is released in the blood by primary and metastatic tumors, one can 
theoretically obtain a full representation of the tumor heterogeneity that is present within each 
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patient. Sausen et. al. demonstrated that somatic mutation calling can be made from ctDNA in 
PDAC patients to determine presence of subclinical, residual or recurrent disease following 
surgical resection. Detection of this ctDNA was correlated to disease progression that even 
predated standard computed tomography imaging by an average of 6 months, suggesting that 
there may be an ability to treat subclinical disease before it is overtly clinically evident based on 
imaging (36). Using ultrasensitive digital PCR techniques, ctDNA was detected in 43% of 
surgically resectable (i.e. lower stage) PDAC patients at the time of diagnosis.  Although this 
study did not examine pre-diagnostic samples in patients prior to a clinical manifestation of 
disease, nonetheless, it provides a potential screening approach through which high-risk 
patients, such as those with family history or germline mutations, can undergo non-invasive 
surveillance for the emergence of PDAC in time for curative surgical options.  
Liquid biopsy has also shown promise in being able to genomically characterize tumors, 
and predict chemotherapy response and resistance using next generation techniques through 
both ctDNA and circulating tumor cells (CTCs) (44-46). One can thus begin to imagine how tumor 
evolution and the emergence of new dominant clones can be identified using these methods to 
guide therapeutic decisions in real time.  
Using genomic sequencing to guide therapy 
The genetic heterogeneity of PDAC as presented above is unequivocally one of the many 
significant contributors to the intrinsic and acquired resistance that is characteristic of these 
cancers (47). Targeting of subclonal populations will only lead to transient effects on tumor 
burden, thus new strategies are required for therapeutic targeting of core pathways that are 
induced by founder events. By targeting convergent phenotypes that can be elucidated through 
genome sequencing of patient tumors, genomic information has the potential to guide individual 
patient therapies and outcomes (48, 49). 
In patients with familial PDAC, information of deleterious germline variants may provide 
some success in the cases of gene mutations in double strand break repair pathways by using 
therapeutics aimed at compromising additional DNA repair mechanisms such as platinum based 
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therapies, mitomycin C, and PARP-1 (poly (ADP-ribose) polymerase 1) inhibitors(50-52). By 
exploiting synthetic lethal approaches, which result in cancer-specific cell death through 
exploitation of cancer-specific molecular aberrations, one can target base excision repair through 
PARP-1 inhibition, leading the accumulation of chaotic DNA damage (53-55). 
The ideal gene target in PDAC is Ras itself as it is the main oncogenic driver in more than 
90% of these tumors, but efforts have so far proven ineffective (56, 57). Synthetic lethality 
screens for KRAS have not been successful, but there has been some data suggesting possible 
targeting of its downstream effectors such as the MEK-ERK MAPK and AKT (protein kinase B) 
signaling pathway (58); unfortunately, recent clinical trials have shown unacceptable levels of 
toxicities in humans when two downstream Ras effectors are inhibited (59).   In the small subset 
of PDAC identified as harboring wild type KRAS, sequencing studies have found mutations in 
genes encoding RAS effector proteins including PIK3CA and BRAF (11). In this small subset of 
cases, targeted therapies using BRAF and PI3 kinase inhibitors may beneficial.  
 Further work still remains to be done to determine all key components that drive PDAC. 
Exploiting nodal signaling pathways vs. attacking genetic heterogeneity head on, may be the 
best strategy in overcoming the advantages pancreatic cancers have over current treatment 
regimens. For now, stratification of subsets of patients based on defined molecular markers into 
clinical trials may prove beneficial in demonstrating the effectiveness of targeted therapies in 
these populations.  
 
Clinically relevant concepts in pancreatic cancer 
While early diagnosis of PDAC remains is an unequivocal unmet need, the clinical reality is that 
85% of patients present with locally advanced or distant metastatic (Stage 3 or 4) disease, 
rendering their cancers inoperable. The standard of care for clinical follow up in PDAC patients, 
for both de novo advanced and recurrent tumors, is to use imaging and one biochemical marker 
(CA19-9). The reasons for this are manifold, including the difficulties of repeatedly sampling a 
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visceral site, the costs involved for an inpatient biopsy (easily in the range of $10,000 in most 
academic centers), and the lack of insurance reimbursement for tissue acquisition beyond the 
initial diagnostic workup. As a result, patients with de novo advanced or recurrent disease are 
treated empirically, with minimal insights into genomic underpinnings of treatment failure, in 
contrast to diseases like lung cancer or melanoma, where tissue accessibility has allowed 
elegant mapping of secondary mutations. In passing, it is also worth noting that the paucity of 
tissues from advanced PDAC patients is an important reason why the pioneering exome 
sequencing studies in PDAC, as well as the ongoing TCGA effort, are almost entirely focused on 
surgically resected tumors.  
Given the visceral location of the pancreas, the only biomarker strategy amenable to widespread 
application in the community and to repeated sampling for monitoring treatment progress, is one 
that is blood-based, since direct tissue biopsy involves skillful and expensive medical 
procedures not applicable for general population screening or monitoring. In terms of currently 
available blood-based biomarkers for PDAC, measurement of the glycoprotein CA19-9 is the 
only FDA approved assay for diagnosis and monitoring. However, in symptomatic patients, 
CA19-9 only has a sensitivity and specificity that ranges in the 70-90%. Thus, it is clearly 
suboptimal for diagnosis in asymptomatic patients, which is the eventual target population of 
interest for early detection. While a multitude of blood-based protein biomarkers have been 
tested in research settings for PDAC, none have yet made it to the clinic besides CA19-9. In 
many instances, this is because they are unable to significantly improve the performance of 
CA19-9, while in other scenarios, confounding variables such as chronic pancreatitis or other 
non-neoplastic entities lead to false positives and obfuscate the results. Recently, there has been 
an increasing reliance on using mutant DNA in serum as a cancer biomarker. The reliance on 
mutant DNA over aberrantly expressed proteins stems from the recognition that somatic 
mutations are pathognomonic of neoplasia, and circulating mutant DNA has not been reported 
in patients with benign tumors or non-neoplastic conditions. Cancers release large quantities of 
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cell free DNA (cfDNA) from their mutant genomes into the circulation, and even though much of 
this cleaved into fragments 150bp or less by nucleases, sensitive PCR assays can be designed 
for detecting “hot spot” mutations in genes such as KRAS, PIK3CA, BRAF, etc.. This is quite 
pertinent for PDAC, where >95% of patients have KRAS mutations in their tumors. Nonetheless, 
a recent study that combined isolation of cfDNA in PDAC patients with a bead-based digital PCR 
technology identified KRAS mutations in 75% of patients with advanced disease, but only in 48% 
with localized tumors  Thus, clearly, while cfDNA has great promise, there is substantial room for 
improvement in assay parameters for patients most likely to benefit from early detection. Another 
limitation of cfDNA, from the context of genomic characterization of advanced tumors, is the 
extensively fragmented nature of the nucleic acids, which precludes its use in most next 
generation sequencing (NGS) platforms. Thus, an ideal “liquid biopsy” biomarker strategy 
for early detection and treatment monitoring in PDAC would: (a) be feasible for application 
using blood samples (1-2 vials) in a Point-of-Care Test (POCT) setting; (b) be paired with ultra-
sensitive and quantitative detection of mutant DNA for purposes of early detection and 
treatment/recurrence monitoring; and (c) provide high quality nucleic acids amenable to NGS. 
We this in mind, we hypothesize that liquid biopsies in the form of cfDNA and exosomal derived 
DNA are a reliable surrogate of the tumor genome in PDAC patients, and can be a biospecimen 
of choice for early detection, serial disease monitoring, and therapeutic stratification, without the 
need for tissue acquisition. We aim to identify mutant DNA in liquid biopsies from patients with 
surgically resectable and metastatic PDAC in order to query the actionable exome of PDAC for 
therapy guidance.  
Exosomes and other extracellular vesicles  
Exosomes are extracellular vesicles (EVs) exhibiting a diameter of 40-120 nm, conceived 
endogenously through the multivesicular endosome pathway and released to the extracellular 
space via fusion with the plasma membrane (60, 61).  Microvesicles (MVs) are a class of larger 
EVs with a diameter ranging from 0.2 to 1 m and originate from the budding and fission at 
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special “lipid raft” domains of the plasma membrane (62).  A methodology to reliably enrich for 
exosomes, but not microvesicles, currently does not exist, as there are significant overlap 
between size, shape, density and cell marker profiles (63).  Both are molecular vehicles reported 
to transfer a variety of biochemical cargo, including protein products, RNA transcripts, 
microRNAs, and fragmented DNA, but beyond their distinct biogenesis pathways and relative 
diameters, the two are difficult to delineate, and as a result, are frequently used interchangeably 
in literature (64-67).  For the purpose of this chapter, we will use the term exosome to refer 
specifically to the population of small EVs produced through the multivesicular endosome 
biogenesis pathway. 
 
Double-Stranded Genomic DNA in Circulating Exosomes 
Circulating exosomes are known to facilitate intercellular communication through the 
exchange of numerous biochemical products such as proteins, lipids, mRNA transcripts, miRNA, 
and DNA of both chromosomal and mitochondrial origin (68).  The recent identification of double-
stranded high molecular weight genomic DNA within circulating exosomes has proven to be an 
exciting discovery in the context of cancer liquid biopsies with translational implications for early 
detection, diagnosis, monitoring, and prognostic and therapeutic stratification of solid tumors, 
including deep seated visceral cancers.  Specifically, exosome-derived DNA (exoDNA) may have 
a role in precision medicine, whereby molecular profiling of exoDNA may lead to the identification 
of effective therapeutic strategies based on the molecular makeup of a patient’s underlying 
cancer from which the exosomes have been released into circulation.  Similar in concept to the 
use of circulating tumor DNA (ctDNA), exoDNA allows for the profiling of an additional liquid 
biopsy compartment, whereby tumor profiling is possible through a minimally invasive approach 
compared to more invasive tumor biopsy procedures, thus allowing for repeated biopsy samples 
taken throughout disease treatment and progression.  
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 The presence of chromosomal DNA cargo within exosomes was validated in exosomes 
isolated from healthy human plasma and from the culture supernatants of HEK293 human 
embryonic kidney cells and K562 human leukemia cells (69).  In this study, isolated exosomes 
were treated with DNase to ascertain that the isolated genomic DNA presided in the interior, 
rather than the exterior of the exosomes, the latter of which would represent the circulating cell 
free DNA (cfDNA) fraction.  Additionally, as opposed to cfDNA, which exists in the form of 
fragmented DNA molecules of ~170bp, exoDNA consisted of high molecular weight DNA.  
Numerous groups have since reported the presence of exosomes enriched with long and/or 
fragmented genomic DNA of varying sizes from different sources, including plasma, urine, and 
pleural effusions, with whole-genome sequencing studies subsequently revealing that exoDNA 
covered the entire compendium of human chromosomes without a bias towards particular 
regions of the genome (69-72). 
 
The shielding of the genomic DNA by the exosome exterior appears to attenuate DNA 
degradation by extracellular DNAses, and enhances the stability of the exoDNA, an observation 
that raises the possibility of using tumor-secreted exosomes paired with next generation 
sequencing (NGS) as a liquid biopsy platform for comprehensive interrogation of the cancer 
genome (73).  Additionally, having the ability to profile DNA from different sources in circulation 
may allow for characterization of differing biological underpinnings that occur during tumor 
progression.  In other words, it is generally believed that cfDNA is released in circulation from 
cells undergoing active apoptosis or necrosis, versus exoDNA that may be derived from cells 
that undergoing rapid proliferation and active biogenesis of exosomes.  A recent study 
hypothesizes a potential mechanism of DNA packaging within exosomes involving the 
enrichment of Histone H2B proteins within exosomes (74).  In other words, these proteins have 
a role in identification of foreign or aberrant cytosolic DNA molecules and have been shown to 
co-localize with exosomal proteins such as CD63, which is involved in exosome cargo trafficking.  
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It is thus thought that exosomes may provide a mechanism for exporting of mutated DNA 
molecules out of the cells as a means of self-defense.   
 
Detection of Mutational Signatures in Genomic DNA-Enriched Exosomes 
Mutation detection within exoDNA of pancreatic cancer patient plasma initially 
demonstrated utility using polymerase chain reaction (PCR) and Sanger sequencing to 
determine trademark KRAS and TP53 mutations, known common genetic drivers of pancreatic 
cancer (70).   Subsequent reports confirmed that Sanger sequencing detection of mutational 
signatures can also be performed in exosomes secreted by prostate cancer cells (75).  For 
prostate cancer patients, this methodology can be applied not only in excreted urine, but also in 
circulation, as high molecular weight exosomal DNA fragments were also identified in the plasma 
of prostate cancer patients (75, 76).  Interestingly, the presence of exosomes has been 
acknowledged in a range of biological fluids including blood, urine, milk, and saliva, creating 
several opportunities for applications that rely on the fluid context, such as the use of exosomes 
in the urine for urinary tract malignancies, exosomes in pleural fluids for lung/mesothelial 
cancers, or exosomes within the blood for visceral malignancies (77) . 
 
Exosomes as Agents for Early Detection, Diagnosis, and Stratification  
In recalcitrant cancers such as pancreatic ductal adenocarcinoma (PDAC), diagnosis 
often occurs at a late stage of the disease when the cancer becomes virtually uncurable.  This is 
typically attributed to the late presentation of disease symptoms and an inability to discern low 
volume (early stage) disease.  Currently, carbohydrate antigen 19-9 (CA 19-9) is the circulating 
tumor marker most commonly used for diagnosis in the clinic.  Because CA 19-9 is not elevated 
in the early stages of PDAC, and is also present in many benign cases of pancreatitis and biliary 
obstruction, it has mostly been used as a prognostic tool to track tumor progression.  As a result, 
new methodologies with the capacity to detect tumors at an early, treatable stage without the 
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direct, invasive sampling of the cancer, are desperately needed to address these types of 
aggressive cancers.  Noninvasive liquid biopsy strategies involving the isolation of circulating 
tumor cells (CTCs) and ctDNA from patient blood to determine the presence of an asymptomatic 
cancer have shown promise, but the diagnostic and early detection potential of circulating 
exosomal DNA (exoDNA) is just beginning to be understood (42, 44, 78).  
 
As the principal driver mutation, KRAS is near ubiquitous in PDAC, with an estimated 
~95% of tumors exhibiting some KRAS mutations (79, 80).  This near ubiquitous presence of 
KRAS in PDAC tumors, and the fact that it represents one of the first mutations that is acquired 
during carcinogenesis, suggests that a strategy for its detection in the context of liquid biopsies 
may provide an avenue for early detection and treatment monitoring (81).  Using an ultrasensitive 
mutation detection methodology known as droplet digital polymerase chain reaction (ddPCR), 
Allenson et al demonstrated the feasibility of detecting KRAS mutations in exoDNA from PDAC 
patients, and determining the circulating mutant allele frequency (MAF) for the oncogenic allele 
amongst a sea of wild type DNA (82).  This study demonstrated the ability to detect mutant alleles 
in exoDNA obtained from all stages of PDAC, as well as allowing for stratification of patient 
survival outcomes based on the KRAS MAF.  Notably, mutation detection of exosomal KRAS 
(exoKRAS) was seen in 7.4% of age matched healthy controls, 66.7% of localized disease, 80% 
of locally advanced disease, and 85% of metastatic PDAC, representing 75.4% sensitivity and 
92.6% specificity for exoKRAS as a tumor biomarker for evaluating PDAC.  Furthermore, a 
patient that tested positive for exoKRAS was 8.17 times more likely to have an early stage cancer 
rather than be tumor-free.  Interestingly, exoKRAS MAF levels correspond with disease-free 
survival in patients with localized disease, where patients with an exoKRAS of >1.0% 
experiencing poorer disease free survival, a relationship that the prognostic biomarker CA 19-9 
did not illustrate.  This suggests that there may be a subpopulation of patients that may require 
more aggressive intervention and follow-up.  
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 In the aforementioned study, it was also notable that exoDNA outperformed ctDNA in the 
detection of PDAC, and generated significantly higher detection rates of positivity across all 
stages of the disease, but most important in the early stages (resectable stages) of cancer.  The 
ddPCR analysis of cfDNA revealed mutant cfKRAS detection in 14.8% of healthy controls, 45.5% 
of localized disease, 30.8% of locally advanced disease, and 57.9% of metastatic PDAC.  A 
possible explanation for this discordance is that ctDNA is theorized to be released extensively 
into circulation only at the later phases of PDAC, where dying cells becomes more pervasive, 
and as a result, may be less effective at pinpointing early stage disease manifestations (83).  
Thus, exoDNA, a product of normal biogenesis pathways, may be a promising alternative to 
ctDNA for the earlier detection of PDAC.  As a cautionary note, mutant KRAS was also found in 
healthy individuals (including two independent cohorts from the US and Europe), a phenomenon 
that appears to increase with age-related clonal hematopoiesis and/or the likely presence of 
KRAS-mutant precursor lesions within the pancreas, GI tract or lung.  This finding serves to add 
an important caveat to the utility of the current methodology as an early diagnostic tool, and 
prevent the phenomenon of “overdiagnosis”.  It is thus important to consider limiting such screens 
to high-risk populations using current assay technologies, or develop methodologies that may 
increase specificity, such as detection of a panel of mutations that represents a higher probability 
for an underlying cancer (as opposed to a clinically insignificant precursor lesion).  
 
Genomic Molecular Profiling of Exosomal Cargo 
A key component of a precision medicine approach to cancer is the ability to profile the 
molecular characteristics of a patient’s underlying cancer.  This is particularly difficult for visceral 
cancers such as PDAC where attempts at surgical sampling of tumor tissue are inherently 
invasive and frequently limited by the obscure tumor location and risk accompanied with surgical 
procedure (84).  Minimally invasive liquid biopsies have been attractive alternatives to direct 
tissue sampling.  Investigators have previously used plasma-derived, cfDNA to identify key 
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oncogenic “hotspot” drivers (ie. BRAF, KRAS, EGFR) via digital PCR, but the highly fragmented 
nature of cfDNA makes applications involving next-generation sequencing (NGS) platforms more 
challenging (85-87).  Though attempts at using cfDNA for targeted genomic profiling have been 
published (and companies such as Foundation Medicine, GRAIL, and Guardant Health are 
heavily investing in such cfDA “liquid biopsy” assays), the feasibility of circulating exosomes as 
means for tumor profiling and disease monitoring has only just begun to be described. 
 
 A recent study sought to determine the efficacy of exosomes in visceral tumor genomic 
profiling (72).  San Lucas et al isolated circulating exosomes from various bodily fluid sources 
including peripheral whole blood and pleural effusions of metastatic PDAC patients.  The 
exoDNA extracted from these exosomes contained genomic DNA of high molecular weight, 
which was representative of the entire human genome (65%-91% genomic representation on 
whole-genome sequencing).  The exoDNA isolates further revealed high representation of tumor 
fraction ranging from 56%-82%, suggesting that this liquid biopsy compartment may confer an 
enriched source of tumor derived material in circulation.  This is further emphasized by the high 
cancer-derived DNA fraction found in exosomes obtained from a pleural effusion (82%) in the 
context of <1% malignant cells on cytospin in the same sample.  Whole exome sequencing of 
exoDNA further revealed several potentially actionable mutations, including COSMIC (Catalogue 
of Somatic Mutations in Cancer) alterations that could be used to monitor tumor genomic 
evolution over time, and COSMIC genes that could be addressed through a particular clinical 
trial or chemotherapy.  Sequencing data of exoDNA also illustrated amplified copy numbers of 
major mutational signatures such as KRAS, EGFR, and ERBB2.  In a particularly interesting case 
demonstrating the potential utility of exoDNA for therapeutic selection, the investigators detected 
an unexpected somatic BRCA2 mutation, known to impair homologous recombination, a critical 
DNA repair mechanism in actively dividing cells.  This patient subsequently achieved a striking 
response to a regimen comprising of cisplatin, a crosslinking agent that generates widespread 
DNA damage.  Although retrospective and correlative in nature, this data suggests that further 
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characterization of how mutation detection through exoDNA can impact therapeutic decision-
making is further warranted.  
 
 In a separate study, Castillo et al describe an enrichment methodology to specifically 
capture cancer-specific exosomes (CSEs) from the circulation, allowing for the ability to perform 
high resolution genomic characterization through the captured cargo (74).  The authors identified 
a panel of six proteins - CLDN4, EPCAM, CD151, LGALS3BP, HIST2H2BE and HIST2H2BF - 
that were specifically expressed on the surface of PDAC-derived CSEs (“surfaceome”), and 
could be exploited through an immunocapture approach for enriching CSEs.  As opposed to 
ctDNA, which cannot be specifically captured from the total cfDNA compartment, exosomes have 
the added benefit of expressing tumor specific markers that can be used to separate tumor and 
normal tissue derived exosomes.  This is particularly relevant in the context of those patients 
undergoing active therapy where circulating tumor burden can dramatically decrease to the point 
of making mutational events in circulation undetectable using current technologies, or in the 
context of early detection of an asymptomatic cancer where the volume of CSEs might be 
overwhelmed by the complement of normal exosomes.  To overcome this limitation, Castillo et 
al applied an antibody cocktail through an immunocapture technique that allowed for positive 
selection of CSEs, which can be subsequently used for mutation detection.  Using this assay, 
they achieved an increase in mutation detection from 44% to 73% in non-captured versus 
captured exosomes.  The authors also demonstrated the utility of this technique in being able to 
perform NGS on CSE-derived exoDNA through a molecular barcoding targeted sequencing 
approach.  In an index case of a patient who initially responded to PARP inhibitor therapy 
secondary to a somatic BRCA2 stop-gain mutation, and subsequently progressed, the authors 
were able to identify a putative mechanism of resistance through a second splice site mutation 
of the same gene, which allowed for reversion of the initial stop-gain (“BRCA2 reversion 
mutation”).  This further demonstrates the ability of exosomes to not only detect genomic 
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vulnerabilities, but also to provide a means to identify mechanisms of resistance for real-time 
precision oncology decision making.  
 
Transcriptomic Characterization of Tumors Through Liquid Biopsies 
 As a source a highly enriched tumor material, exosomes also contain a milieu of cargo 
that can be used for tumor characterization, such as mRNA.  Whereas cfRNA is largely 
comprised of highly fragmented circulating RNA transcripts, limiting the molecular assays to 
those involved in microRNA detection, RNA within exosomes (exoRNA), provides a source of 
long mRNA transcripts that allow for more detailed characterization of tumors through liquid 
biopsies.  In the study by San Lucas et al, exoRNA allowed for the orthogonal validation of gene 
amplifications, as in the case of overexpression of ERBB2 (72).  In addition, the benefits of this 
transcriptome-based approach may also extend towards the determination of novel cancer-
specific fusion transcripts that may otherwise not be apparent from genomic sequencing only.  
Further, the identification of expressed cancer-derived neoantigens (both missense mutations 
and fusions) may facilitate emerging precision immunotherapies that rely on discovery of such 
neoantigens in a patient-specific manner.  Ultimately, this may also allow for profiling of the 
dynamic changes in the neoantigen repertoire, which may occur from selective pressures and 
“antigen editing” that occurs during tumor progression.  Through serial monitoring of tumor 
associated antigens and how these evolve over time, one can begin to suggest novel therapeutic 
approaches relating to ideal immunotherapeutic stratification.  Specifically, quantitative estimates 
of neoantigen load through liquid biopsies may provide an early surrogate of response to 
immunotherapies such as vaccines or engineered T-cell receptors, of which there is currently no 
readily available biomarker. 
 
Conclusions 
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Next-generation sequencing of circulating exosomes (including enriched CSEs) provides 
promising strategies for non-invasive tumor profiling and disease monitoring.  Recent data from 
many laboratories suggests that exosomes are an important component of liquid biopsies, 
facilitating identification of actionable mutations critical to developing patient-tailored precision 
treatment regimens.  In addition, the ability of exoRNA to profile the tumor transcriptome presents 
many new exciting opportunities, such as the discovery of novel neoantigens that may serve as 
the basis for emerging adoptive T-cell immunotherapies.  This system also exhibits high clinical 
relevancy with abridged times from patient blood draw to exosome sequencing and data analysis.  
These promising data warrants the further development of exosomes as a complementary 
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Chapter 2 – Materials and Methods  
Cell lines and culturing 
PATC43, PATC66, and PATC92 were established from patient derived tumor xenografts (88). 
These lines were maintained in RPMI-1640 medium with 10% FBS. MIAPaCa-2, Pa01C, Pa02C, 
Pa03C, Pa04C, Pa07C, Pa08C, Pa09C, Pa021C, and Pa028C are established pancreatic 
cancer cell lines from primary or metastatic tissue (10). These lines were maintained in DMEM 
medium with 10% FBS. Non-neoplastic cell lines used include HPNE, an hTERT-immortalized 
human pancreatic epithelial line; CAF19, an immortalized cancer-associated fibroblast line from 
a PDAC patient; and SC2, an immortalized fibroblast line established from non-neoplastic 
pancreas tissue (89, 90). CAF19 and SC2 were maintained in DMEM medium with 10% FBS. 
HPNE was grown in 75% DMEM without glucose, 25% Medium M3 Base (Incell Corp. Cat# 
M300F-500), 5% FBS, 10ng/ml human recombinant EGF, and 5.5mM D-glucose (1g/L). 
 
Exosome isolation from cell lines 
PDAC and non-neoplastic pancreas epithelial cell lines were cultured in HYPERflasks in 
respective medium (Corning). Upon reaching 70% confluency, cell lines were starved of 10% 
FBS for 48 hours and media supernatant was harvested. In summary, 4000mL of media was 
centrifuged serially at 1000 RPM for 10 minutes at  4°C, where cell pellets were discarded and 
then the supernatant centrifuged at 5000 RPM for 10 minutes at 4 °C to remove cellular debris 
(Figure 1).  Resultant supernatant was filtered through a 0.22 μm pore filter, then ultracentrifuged 
at 154,000g at 4 °C overnight. The resulting pellet was resuspended in 66 ml of PBS with a 
subsequent ultracentrifugation step performed at 154,000g at 4 °C for 2 hours. The resulting 
exosome pellet was resuspended in 100ul of PBS and harvested for downstream analyses 
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Exosome isolation from patient samples 
Three 8.5ml Acid Citrate Dextrose tubes (BD) of blood were collected from each patient. The red 
blood cells and plasma were separated by centrifuging blood samples at 2500 rpm for 10 minutes 
at room temperature. On average, a total of ~11.7ml of plasma was obtain and diluted in PBS to 
50mls. The plasma was centrifuged at 1000 rpm for 5 minutes, then the supernatant was 
decanted and centrifuged at 5000 rpm for 10 minutes to remove the remaining cellular debris. 
The plasma solution was split between 3 ultracentrifuge tubes, diluted in PBS to a maximum 
volume of 66ml and spun overnight at 154,000xg. The plasma pellet was washed with PBS and 
spun in the ultracentrifuge for 2 more hours at 154,000xg. The supernatant was discarded and 
the exosome pellets were collected by resuspending in 600ul of PBS. Exosomes in the “total 
exosome control cohort” were processed immediately for DNA isolation using the QIAamp 
Circulating Nucleic Acid Kit (Qiagen, Cat# 55114) per the manufacturer’s protocol. Exosomes 
samples within the “Captured exosomes” cohort were processed as described below.  
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DNA isolation and mutation detection 
Cell-free DNA (cfDNA) was isolated using the QIAamp Circulating Nucleic Acid Kit (Qiagen) 
according to the manufacturer’s protocol.  In selected samples in which cfDNA was not initially 
detected, cfDNA was subsequently amplified using the RepliG Cell WGA kit (Qiagen) according 
to the manufacturer’s protocol. ExoDNA was isolated using the MagAttract High Molecular 
Weight DNA kit (Qiagen) according to the manufacturer’s protocol. DNAase I treatment of 
exosomes was performed as previously reported to confirm extraction of DNA from the exosome 
compartment and not cfDNA[1].  In select samples in which gene mutations were not initially 
detected in exoDNA, whole genome amplification was performed using the RepliG Cell WGA kit 
(Qiagen) according to the manufacturer’s protocol. 
 
 
Figure 1: Exosome isolation scheme from cell culture media and human plasma for 
downstream analysis  
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Digital PCR 
Droplet digital PCR (ddPCR) (QX200; BioRad, Hercules, Calif) was used for highly sensitive 
detection of genetic mutations with a multiplex KRAS assay containing G12V, G12D, G12R, 
G12C, G12S, G12A, G13D mutant codons. Estimation of false-positive rate (FPR) was first 
determined across multiple wells containing KRAS wild type DNA from a healthy individual as 
well as a non-template control (NTC). A cutoff of more than 2 droplets in the mutant channel was 
determined to be optimal for providing no FPR and classifying a sample as having mutant 
molecules. A lower limit of detection (LOD) was then determined of 0.01% MAF (Figure 2). 
Subsequently, for each experiment done on clinical samples, wells containing a positive control 
and two negative controls were included to determine the absence of contamination and PCR 
efficiency of the ddPCR probes in each plate. Positive controls consisted of one of either 
pancreatic cell line (Pa04C or Panc1), while the negative controls included a wild-type well of 
DNA from a healthy individual and a well with just water as a non-template control. Interpretation 
and analysis of results was done in accordance with BioRad Rare Mutation Detection Best 

































Figure 2 Low limit of detection of KRAS mutations through droplet digital PCR 
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Statistical analyses 
Statistical analyses were performed using the R and SAS programming languages.  Descriptive 
comparisons of study variables used the Fisher’s exact test for categorical data and the Wilcoxon 
rank sum test for continuous data.  Univariate analyses using Cox proportional hazard models 
were performed to examine potential clinical and molecular factors contributing to survival.  
Survival curves were generated using the Kaplan-Meier method, and log-rank tests were used 
to compare survival curves.  Clinical outcomes were established as defined by the National 
Cancer Institute (91).  KRAS sensitivity and specificity was determined as related to the patient’s 
cancer status.  
 
Exosome Protein Fractionation 
Exosome surface and cargo proteins were isolated from the same sample (Figure 3). To isolate 
exosome surface from cargo proteins, the exosome pellet was biotinylated with 5 ml of 1 mg/ml 
of Sulfo-NHS-SS-BIOTIN (Pierce) in PBS for 30 min at 4 °C. The residual biotinylation reagent 
was quenched with 10mL of 100 mM lysine in cold PBS for 15 min at 4 °C. Biotinylated exosomes 
were recovered through ON ultracentrifugation at 100,000 g. Biotinylated exosomes were then 
sonicated in 2 ml of 4M Urea, 3% IsoPropanol, 20 mM Tris, 2% OG and protease inhibitors 
(complete protease inhibitor cocktail, Roche Diagnostics) followed by centrifugation at 20,000 g 
at 4 °C for 30 min. Biotinylated proteins were isolated by affinity chromatography using 2 ml of 
UltraLink Immobilized Neutravidin (Pierce) according to the manufacturer’s instructions. Proteins 
bound to the column were recovered by reduction of the biotinylation reagent with 1 ml of a 
solution containing 65 µmol of DTT and 2% (w/v) OG detergent overnight at 4 ºC and referred to 
as exosome surface proteins. Proteins not bound to the column (flow through) were also collected 
and named cargo proteins. Exosome surface and cargo proteins were fractionated by reversed-
phase chromatography, using the same amount of proteins across different samples for a given 
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exosome compartment. All three extracts were reduced by DTT and alkylated with 
iodoacetamide prior to chromatography. Separation were performed in an off-line 1100 series 
HPLC system (Shimadzu) with reversed phase column (4.6 mm ID × 150 mm length, Column 
Technology Inc) at 2.7 ml/min using a linear gradient of 10 to 80% of organic solvent over 30 min 
run. Solvent system used was: aqueous solvent – 5% acetonitrile / 95% water / 0.1% of 
trifluoroacetic acid; organic solvent – 75% acetonitrile / 15% isopropanol / 10% water / 0.095% 
trifluoroacetic acid. Fractions were collected at a rate of 3 fractions per minute. 
  
Figure 3: Schematic representation of surface exosome protein extraction 
  33 
Mass Spectrometry Analysis 
Each fraction from the reverse phase chromatography were in-solution digested overnight at 37 
°C with 400 ng of trypsin. The resulting trypsinized fractions were pooled into 4 to 10 pools based 
on chromatographic features. Pools were individually analyzed by LC-MS/MS. LC-HDMSE data 
were acquired in resolution mode with SYNAPT G2-S using Waters Masslynx (version 4.1, SCN 
851). The capillary voltage was set to 2.80 kV, sampling cone voltage to 30 V, source offset to 
30 V, and source temperature to 100°C. Mobility utilized high-purity N2 as the drift gas in the IMS 
TriWave cell. Pressures in the helium cell, Trap cell, IMS TriWave cell, and Transfer cell were 
4.50 mbar, 2.47e-2 mbar, 2.90 mbar, and 2.53e-3 mbar, respectively. IMS wave velocity was 
600 m/s, helium cell DC 50 V, Trap DC bias 45 V, IMS TriWave DC bias V, and IMS wave delay 
1000 μs. The mass spectrometer was operated in V-mode with a typical resolving power of at 
least 20,000. All analyses were performed using positive mode ESI using a NanoLockSpray 
source. The lock mass channel was sampled every 60s. The mass spectrometer was calibrated 
with a [Glu1] fibrinopeptide solution (300 fmol/µL) delivered through the reference sprayer of the 
NanoLockSpray source. Accurate mass LC-HDMSE data were collected in an alternating, low 
energy (MS) and high energy (MSE) mode of acquisition with mass scan range from m/z 50 to 
1800. The spectral acquisition time in each mode was 1.0 s with a 0.1-s inter-scan delay.  In low 
energy HDMS mode, data were collected at constant collision energy of 2 eV in both Trap cell 
and Transfer cell. In high energy HDMSE mode, the collision energy was ramped from 25 to 55 
eV in the Transfer cell only. The RF applied to the quadrupole mass analyzer was adjusted such 
that ions from m/z 300 to 2000 was efficiently transmitted, ensuring that any ions observed in the 
LC-HDMSE data less than m/z 300 arised from dissociations in the Transfer collision cell. The 
acquired LC-HDMSE data were processed and searched against protein knowledge database 
(UniProt) through ProteinLynx Global Server (PLGS, Waters Company) with 4% False Discovery 
rate. Each dataset was normalized to the total number of spectral counts of the each 
compartment. 
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PDAC specific “surfaceome” profiling of exosomes 
Proteins that were expressed at a higher prevalence in normal samples compared to tumor 
samples in ExoCarta were filtered out, resulting in 139 PDAC-specific exosomal surface protein 
markers (corresponding to 103 genes; Supplementary table 2).  Subsequently, we identified 
three additional “borderline” proteins in our initial PDAC-specific exosomal marker list that did not 
meet these filtering criteria: CD151, UBA52 and HIST2H2BF, but have been previously described 
in the context of exosomes and tumorigenesis (CD151) (92), were found in a high proportion of 
cancer cell lines (11/13) even though being found in one non-neoplastic line (UBA52), or have 
biological and complementary relevance to other identified candidates HIST2H2BF (93). We then 
manually selected candidates for pull-down that were collectively represented across all of the 





Antibody coating of beads was performed with 3ul of Aldehyde/Sulfate latex beads resuspended 
in 500ul PBS and incubated with 200ug of primary antibody anti-Histone H2B (Mouse monoclonal 
mAbcam 52484, Abcam), Anti-CD151 (Mouse monoclonal  11G5a, AB33315, Abcam),   anti-
LGALS3BP (Mouse monoclonal 3G8, AB123921, Abcam), anti Epcam, (Mouse monoclonal 
AUA1, AB20160, Abcam) or anti Claudin-4 (Mouse monoclonal 3E2C1, Thermo-Scientific) per 
1ml of beads and incubated overnight at 4C on a Eppendorf ThermoMixer® C. The following day, 
500ul of 1% BSA was added and incubated for 30 minutes. Coated beads were then pelleted 
down through centrifugation at 12,000RPM for 5 minutes. Pellet was resuspended in 1ml of 
1%BSA 100mM Glycine solution for 30 minutes followed by centrifugation at 12,000 RPM for 5 
minutes. Pellet was resuspended in 200ul of 1%BSA and incubated with samples of patient 
derived exosomes overnight at 4C. Exosome coated beads were centrifuged at 12,000 RPM for 
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5 minutes and washed 3 times with 800ul of 1% BSA. For flow cytometry analysis, resulting 
exosome attached beads were stained with PE conjugated Mouse Anti-Human CD63 (BD 
Bioscience, #556020). Isotype control was stained by Simultest IgG2a/IgG1 (BD Bioscience, 
#340394).  Flow cytometry was performed on an Accuri C6 System (BD Bioscience) and 
analyzed on Flow Jo software. For DNA isolation, washed pellet was resuspended in appropriate 
lysis buffer for DNA isolation using the QIAamp Circulating Nucleic Acid Kit (Qiagen, Cat# 55114) 
per the manufacturer’s protocol. 
 
Electron microscopy 
Microscopy imaging was performed in the High Resolution Electron Microscopy Facility at MD 
Anderson. In summary, exosome-diluted aliquots were fixed in Formaldehyde/Glutaraldehyde, 
2.5% each in 0.1M Sodium Cacodylate Buffer, pH 7.4 for 15 minutes. For TEM imaging, samples 
were placed on 100 mesh carbon coated, formvar coated copper grids treated with poly-l-lysine 
for approximately 1 hour. Samples were then negatively stained with Millipore-filtered aqueous 
1% uranyl acetate for 1 min. Stain was blotted dry from the grids with filter paper and samples 
were allowed to dry. Samples were then examined in a JEM 1010 transmission electron 
microscope (JEOL, USA, Inc., Peabody, MA) at an accelerating voltage of 80 Kv. Digital images 
were obtained using the AMT Imaging System (Advanced Microscopy Techniques Corp., 
Danvers, MA). For SEM images, fixed samples were placed on round coverslips treated with 
poly-l-lysine for approximately 1 hour, washed with 0.1 M cacodylate buffer, pH 7.3, post fixed 
with 1% cacodylate buffered osmium tetroxide, washed with 0.1M cacodylate buffer, then in 
distilled water. Afterwards, the samples were sequentially treated with Millipore-filtered 1% 
aqueous tannic acid, washed in distilled water, treated with Millipore-filtered 1% aqueous uranyl 
acetate, then rinsed thoroughly with distilled water. The samples were dehydrated with a graded 
series of increasing concentrations of ethanol, then transferred to graded series of increasing 
concentrations of hexamethyldisilazane (HMDS) and air dried overnight. Samples on coverslips 
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were mounted on to double-stick carbon tabs (Ted Pella. Inc., Redding, CA), which have been 
previously mounted on to aluminum specimen mounts (Electron Microscopy Sciences, Ft. 
Washington, PA). The samples were then coated under vacuum using a Balzer MED 010 
evaporator (Technotrade International, Manchester, NH) with platinum alloy for a thickness of 25 
nm., then immediately flash carbon coated under vacuum. The samples were transferred to a 
desiccator for examination at a later date. Samples were examined in a JSM-5910 scanning 
electron microscope (JEOL, USA, Inc., Peabody, MA) at an accelerating voltage of 5 kV. 
 
Exosomes size distribution measurement 
Exosomes were resuspended in PBS and serially diluted to the optimum dynamic range of the 
Zetaview nanoparticle analyzer (Particle Metrix, Diessen, Germany) for measurement of size and 
particle density. Observed and tracked particles were incorporated into size distribution 
calculations according to the particles’ Brownian motion. The diffusion constant is then calculated 
and transferred into a size histogram via the Einstein Stokes relation between diffusion constant 
and particle size. For calculation of exosome concentrations, exosome yield was extracted by 




Plasma exosomes were captured using the CD63+ Dynabead exosomes isolation kit according 
to manufacturer's instructions (Invitrogen, Life Technologies #10606D). Flow analysis of patient 
exosomes bound to Dynabeads conjugated with antibody was done according to the 
manufacturer's protocol. Briefly, 10 µl of exosomes were incubated with 90 µl of CD63+ 
Dynabeads overnight at 4°C. A Dynabead magnet was then used to positively select for bound 
exosomes, which were then stained with PE Mouse Anti-Human CD63 (BD Bioscience, 
#556020). Isotype control was stained by Simultest IgG2a/IgG1 (BD Bioscience, #340394). Flow 
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cytometry was performed on an Accuri C6 System (BD Bioscience) and analyzed on Flow Jo 
software (v.10.0.7). 
 
Western Blot Analyses 
Proteins extracted from the human cell lines SC2, CAF-19, PA01C, Pa03C and Pa04C and 
exosomes from the respective cell lines were used to examine different protein markers. 
Exosomes were lysed with RIPA buffer 1x (Sigma-Aldrich) and 1x Protease Inhibitor Cocktails 
(Sigma-Aldrich). Sample loading was normalized according to Bradford relative protein 
quantification. The proteins were mixed NuPAGE® LDS Sample Buffer (4X) and 10x NuPAGE® 
Sample Reducing Agent (Invitrogen) to a final concentration of 20ug(per sample), then heated 
at 70°C for 10 min and loaded onto a 1.0 mm × 10 well 4–12% Tris-Glycine gel (Novex) and thus 
the proteins were separated following an electrophoretic gradient across polyacrylamide gels. 
The gel was run under denaturing conditions at 180 V for 1h and then transferred nitrocellulose 
membrane (Bio-Rad) using the Trans-Blot® Turbo™ Transfer System with and 1x transfer buffer 
10% with ethanol at 1.3Ampers - 25Volts – 8Minutes. The protein blot was blocked for 1 h at 
room temperature with 5% non-fat dry milk in PBS/0.05% Tween and incubated overnight at 4 
°C with the following primary antibodies 1:1000 anti-Histone H2B (Mouse monoclonal mAbcam 
52484, Abcam), 1:1000 Anti-CD151 (Mouse monoclonal 11G5a, AB33315, Abcam), 1:1000 anti-
LGALS3BP (Mouse monoclonal 3G8, AB123921, Abcam), 1:1000 anti CD63 (Mouse monoclonal 
TS63, AB59479, Abcam), 1:1000 anti Epcam, (Mouse monoclonal AUA1, AB20160, Abcam), 
1:1000 anti GPC1 (Rabbit polyclonal, PA5-24972 Thermo-Scientific), 1:1000 anti Claudin-4 
(Mouse monoclonal 3E2C1, Thermo-Scientific), 1:1000 anti GAPDH (Rabbit monoclonal 
EPR16884, AB181603, Abcam), 1:1000 anti TSG-101 (Mouse monoclonal 4A10, AB83, Abcam). 
Afterwards, secondary antibody goat anti-rabbit IgG-HRP (sc-2004, Santa Cruz) or secondary 
antibody goat anti-mouse IgG-HRP (sc-2005, Santa Cruz) were used. The membranes were 
incubated for 1 h at room temperature. Membranes were cleared after antibody incubations in 
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an orbital shaker four times at 5-min intervals with PBS 0.05% Tween20. Clarity™ Western ECL 
substrate Chemiluminescence kit was utilized on the next step; Membranes were developed for 
10 seconds to 1 min and the picture was analyzed. 
 
Whole exome, genome, and transcriptomic sequencing 
For each patient we performed whole genome, exome and transcriptome sequencing on their 
exoDNA and exosomal mRNA.  We also performed exome sequencing of the peripheral blood 
mononuclear cells (PBMCs) for each patient for use as a reference in determining the somatic 
status of identified events.  DNA was captured for exome sequencing using the Agilent 
SureSelect Clinical Exome Kit and subsequently sequenced on an Illumina HiSeq 2500 by the 
Avera Institute for Human Genetics to a mean sequencing depth of 490, 256 and 133 for LBx01-
03 exoDNA and 60x for PBMC DNA using 100-base paired-end reads.  Custom bioinformatics 
pipelines were applied to raw Illumina HiSeq reads for analyzing the patient exomes, including 
the metastatic lung tissue exome sequencing reads provided by Dr. Arul Chinnaiyan at the 
University of Michigan.  Briefly, for DNA sequencing read alignment, the Burrows-Wheeler 
Aligner (BWA) (94) is used for initial alignment to the human genome reference build hg19, Picard 
is used for manipulating and preprocessing Sequence Alignment/Map (SAM) format files (95), 
and the Genome Analysis Toolkit (GATK) (96) is used to perform local realignment of sequencing 
reads.  For the metastatic lung RNA-seq (reads provided by Dr. Arul Chinnaiyan) and the 
exoRNA, cDNA reads were aligned using RNA-Seq by Expectation-Maximization (RSEM) (97).  
LBx01 cDNA alignment resulted in 1101228222 mapped reads.  LBx02 had 118429984 mapped 
reads, and LBx03 had 274391009 mapped reads. 
 
Identification of somatic events 
Given the aligned reads, MuTect was run on exosome and PBMC sample pairs for the sensitive 
detection of point mutations (98). In a similar analysis, the metastatic lung tissue exome from 
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LBx01 was compared with the corresponding PBMC exome.  IndelLocator was used to identify 
small somatic insertions and deletions using similar “tumor/normal” paired analyses (96). 
Somatic mutation reports were generated and filtered using Variant Tools (99), which annotated 
our mutations with information from COSMIC (100), dbNSFP (101), the 1000 Genomes Project 
(102), the Exome Sequencing Project (103), ClinVar (104) and potentially actionable gene lists 
from Jones et al (105) and MD Anderson Cancer Center (unpublished).  Gene fusion events 
were detected in RNA-sequencing data using ChimeraScan (106). 
 
Filtering and annotation of somatic mutation calls 
Using a probabilistic model that is dependent on read quality, sequence context and allele 
counts, MuTect provides a PASS or REJECT status for each putative mutation.  We filtered out 
point mutations with non-PASS statuses.  To help control for false-positives point mutations and 
indels, we required a minimum read depth of 20x in the germline and exoDNA to make a positive 
call.  Any mutation that had at least 1 mutant read in the normal DNA was filtered out.  We 
explicitly attempted to filter out exoDNA false-positive mutations that might be germline variants 
missed in the PBMC data (or common polymorphisms) by cross-checking candidate mutations 
against population variant annotations (including the 1000 Genomes project and the Exome 
Sequencing Project), where we removed mutation calls seen in 1% or more of the samples in 
these population-level projects.  We visually verified nonsynonymous mutations using the 
Integrated Genomics Viewer (IGV) (107).  For each patient, we performed visual verification on 
events by inspecting the sequencing reads at each candidate mutation site across all of that 
patient’s samples.  These QC filters were relaxed in cases where the mutation was seen with 
high frequency (at least 10 times) in the COSMIC database.  The set of mutations used for 
estimation of mutation rates include those point mutations that passed this filtering step with the 
additional removal of mutations with less than a 5% mutant allele frequency to try to globally 
control for false positives. 
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Potentially clinical somatic events 
Only nonsynonymous SNV, stopgain and frameshift insertions and deletions in exoDNA (called 
from exome sequencing) were considered for potential actionability.  Mutations residing in a list 
of actionable genes, an aggregate list of actionable genes composed of those from Jones et al 
2015 (105) and a list compiled from MD Anderson experts were annotated as potentially 
actionable.  To help control for false positives, from the remaining mutations with a 5% mutation 
allele frequency or less, potential actionable mutations had to be seen in COSMIC or verified in 
the patient exosomal mRNA or exoDNA (through whole genome sequencing) to be considered 
as a candidate for potential actionability. 
 
Identification of cancer-associated copy number events 
Copy-number events were called using control-FREEC 7.2 on whole genome sequencing data 
with unpaired samples (108).  A list of cancer-associated genes was downloaded from the 
Cancer Gene Census from the COSMIC database.  Coordinates for each gene for the start and 
end of transcription were retrieved from the UCSC Genome Browser (hg19) (109).  We 
intersected the coordinates of the copy-number events with the maia transcription coordinates of 
the cancer-associated genes and assigned the estimated copy-number (from control-FREEC) to 
each gene that had overlapping coordinates with the event.  The data were subsequently 
visualized using a custom R script. 
 
Estimation of tumor fraction and ploidy of exoDNA 
We analyzed paired exome data from exoDNA and PBMC DNA using Sequenza 2.1.0 to 
estimate tumor fractions and ploidy (110).  Sequenza is an implementation of a probabilistic 
model that incorporates average depth ratios between tumor and normal samples and allele 
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frequencies at germline heterozygous positions to segment DNA into copy number variant 
regions while estimating tumor cellularity and ploidy.  The log posterior probability (LPP) of the 
observed copy number and allele frequencies are calculated by Sequenza for a range of 
candidate ploidy and cellularity values.  The point estimate is given for the ploidy and cellularity 
with maximum LPP.  The 95% confidence range is a region of point estimates with a total 
posterior probability of greater than 0.95.  In the liquid biopsy context, exoDNA represents the 
tumor sample and PBMC DNA the normal sample in the Sequenza configuration, and for 
interpretation we use the tumor cellularity estimate as an estimate of the tumor fraction in the 
exoDNA.  To run Sequenza, we first generated a GC content profile for the human genome hg19 
using a window size of 50 base pairs.  Then for each patient, we generated depth profiles for 
both the exoDNA and the PBMC DNA using the mpileup command of SamTools 0.1.19 (95) for 
subsequent processing using Sequenza. 
 
Gene quantification and fusion detection 
RNA-seq reads were aligned and quantified using RSEM (97).  Expressed transcripts were 
checked for overrepresentation of GO terms and biological pathways using the DAVID 
Bioinformatics resource (111).  The enrichment program is limited to 3000 genes as a maximum, 
thus, for the plasma exosomes samples, the expressed transcripts were limited to those 
expressed at larger than 10 TPM.  For the pleural effusion sample, transcripts expressed at 50 
TPM or more were included.  This allowed for the approximately top 3000 expressed transcripts 
for each sample to be included in the enrichment analyses.  The TPM threshold for the pleural 
effusion exosomes is higher because it was more deeply sequenced compared to the plasma 
samples. Gene fusions were called using ChimeraScan 0.4.6 on RNA-sequence data (106).  The 
reference transcriptome (UCSC known genes) was downloaded from the chimerascan download 
site (http://chimerascan.googlecode.com/files). Only those events in the plasma samples with at 
least 10 read pairs (and 20 read pairs in the pleural effusion sample) were included as candidate 
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fusion events.  Again, because of the deeper sequencing of the pleural effusion sample, the 
threshold used was higher. 
 
Mutation signatures 
We characterized mutational signatures using 6 base substitutions (i.e., C>A, C>G, C>T, T>A, 
T>C, and T>G) and their 5′ and 3′ bases adjacent to the mutation site, generating 96 
combinations of substitutions.  Coordinates and base substitutions for each sample for all 
mutations were fed into a custom R script that utilizes the SomaticSignatures package to retrieve 
adjacent bases from a genome reference for each mutation (112).  Previous studies have 
identified existing mutational signatures across various types of cancers, which have since been 
included in the COSMIC database (100, 113).  We downloaded 30 mutation signatures from the 
COSMIC database and visually assessed similarities of pancreatic and lung cancer signatures 
with our signatures.   
 
Next generation sequencing with molecular barcodes 
Illumina NGS libraries were prepared from enriched plasma derived exosomal DNA and genomic 
DNA. A total of 10-80ng of DNA was used for library construction through the QIAseq Targeted 
DNA Panel (Qiagen, Cat# DHS-3501Z) which employs a molecular barcoding approach. First, 
genomic DNA samples were fragmented, end repaired and A-tailed. The DNA fragments were 
then ligated at their 5’ ends with Illumina adapters containing a 12-bp Unique Molecular Index 
(UMI) and sample index. These fragments underwent target enrichment PCR - with 11,311 gene-
specific primers and one universal forward primer complementary to the adapter sequence. 
Afterwards, the library is further amplified through universal PCR. 
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Bioinformatics with molecular barcodes 
The 12-bp barcode provides a possibility of 16,777,216 unique indexes. After mapping to the 275 
genes in the QIAseq Targeted DNA panel there is sufficient entropy that the chances of overlap 
in of both barcode and template start/stop locations is negligible. Post-amplification, the reads 
are grouped according to loci and barcodes. The duplicates are then condensed into ‘Super 
Reads’ based on the consensus sequence of each barcode. The selection of this consensus 
sequence removes a majority of amplification and sequencing errors.  
The Illumina sequencing data was analyzed through Qiagen’s Biomedical Genomics Workbench. 
The raw output data was initially processed through the standalone workflow ‘Prepare Raw Data’ 
to trim any remnants of the Nextera Trim Adapters. Post-trimming, the reads were run through 
the ‘QIAseq DNA V3 Panel Analysis’ ready-to-use Workflow. This workflow employs the following 
steps: First, PCR adapters are trimmed before the sequences are annotated with their UMI’s. 
The sequences are then mapped to a reference using BWA-MEM (114)  before being grouped 
according to their UMI’s. These groups are then used to create ‘Super Reads’ which are further 
processed to remove ligation artifacts and identify any structural variants. Then, these reads 
undergo local realignment using the Smith-Waterman algorithm before a primer trimming step. 
Finally, a low frequency variant detection workflow is utilized to identify variants using smCounter, 
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Introduction 
Pancreatic ductal adenocarcinoma (PDAC) composes 85% of all pancreatic malignancies and is 
associated with a dismal 5-year survival of 6% (116, 117).  While cancer prevention initiatives 
and advances in targeted therapies have produced tangible survival improvements in breast, 
colon, and lung cancers, long-term PDAC survival remains poor and the nature of the disease 
does not readily present opportunities for screening and early detection (118-123).  Under the 
best of circumstances, resection of early stage disease at experienced and high-volume centers 
improves 5-year survival to only 24-29% (117, 124-126).   
  
Given the aggressive and recalcitrant clinical course of pancreatic cancer, many efforts have 
focused on identifying novel protein, DNA or RNA biomarkers to serve as a means for early 
detection or prognostic stratification (127).  Blood-based liquid biopsy is particularly attractive in 
the context of PDAC, as the primary tumor itself is not routinely accessible in its retroperitoneal 
location, and sampling of the tissue is not without morbidity.  Circulating tumor DNA and KRAS 
genetic mutations as a surrogate for PDAC-specific genetic material has been previously studied 
(128-136), and a study by Bettegowda et al, using a bead-based ultrasensitive PCR assay, 
demonstrated 48% and 77% detection rates for patients with early and late stage tumors, 
respectively (42).   
  
Other reservoirs of proteins, DNA, and RNA have recently been identified in the form of 
microvesicles termed exosomes (72, 137, 138).  Exosomes are 40-150nm lipid bilayer 
membrane bound particles derived from specific biogenesis pathways within cells and accessible 
within the plasma of the circulating peripheral blood (139). Biologically, exosomes have been 
shown to be capable of intercellular communication and modulation of the tumor 
microenvironment (67, 140). Perhaps more importantly, it is believed that the contents contained 
within these particles remains distinct from the remainder of the peripheral blood and thus, might 
represent an enrichment of tumor-specific genomic material (72, 137).  While many have 
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commented on the utility of “circulating tumor” or “cell-free” DNA (cfDNA) in the context of liquid 
biopsy for cancer, here we tested the potential for exosome-derived DNA (exoDNA) to represent 
an additional blood-based compartment which may be complementary to cfDNA in the diagnosis 
and therapeutic stratification of patients with pancreatic cancer. 
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Study populations 
Discovery cohort 
Whole blood samples were collected at MD Anderson Cancer Center (MDACC) through informed 
consent following institutional review board (IRB) approval (PA14-0552). Patients with all stages 
of pancreatic cancer were included in the study.  Healthy control samples were obtained from 
volunteers in the clinic waiting rooms, and for the most part, are relatives of the patients.  
Demographic information and personal medical history was collected from these volunteers, but 
samples were de-identified after collection, so follow-up of these volunteers was not possible.  
Individuals with diabetes, a history of pancreatitis, or a family history of pancreatic cancer were 
excluded from the discovery cohort. Whole blood was collected in green top (Sodium Heparin, 
BD Vacutainer) tubes.  Blood samples were centrifuged at 2500xG for 10 minutes for plasma 
isolation and then stored at -80 degree until the time of exosome isolation. Samples were 
collected between 2003 and 2010, and between 0.9 and 1.5ml of plasma were available per 
patient for both cfDNA and exoDNA analysis.  Medical records were queried for the American 
Joint Committee on Cancer staging, treatment status, and clinical outcomes.  Staging 
considerations were supplemented with National Comprehensive Cancer Network guidelines 
with regard to borderline-resectable tumors.  A total of 68 patients with PDAC of all clinical stages, 
an additional 20 PDAC patients initially staged with localized disease, with blood drawn after 
resection for curative intent, and 54 age-matched healthy controls were included in this cohort. 
 
Validation cohort 
A total of 39 early stage PDAC patients and 82 age-matched healthy controls were recruited 
through an International Agency for Research on Cancer (IARC) case-control study coordinated 
in the Czech Republic and Slovakia following informed consent.  Researchers were blinded to 
the cancer-status of the clinical samples at the time of processing and data analysis. Peripheral 
blood was collected in EDTA tubes at the time of consent and processed as rapidly as possible.  
Blood samples were centrifuged at 2000xG for 10 minutes for plasma isolation and then stored 
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at -80 degree until the time of exosome isolation, where 200ul of plasma were available for 
exoDNA analysis.   
 
Results 
Exosome size and concentration 
The presence of extracellular vesicles in exosome isolations was confirmed by means of 
Zetaview nanoparticle tracking analysis, western blot for exosomal markers, and scanning and 
transmission electron microscopy, with the latter in selected samples (Figure 4).  Average 
particle size was greater among patients with PDAC compared to healthy controls.  Further, 
average particle size was observed to be greater with more advanced disease (Figure 4B), 
particularly, those particles that were between 141 to 220 nm (Figure 4C).  Exosome 
concentration was defined as number of exosomes per mL plasma.  A cutoff value of 5.0 x 10^9 
exosomes was identified through this discovery cohort and found to be associated with overall 
survival for both localized and metastatic patients, with a higher exosome concentration 
predicting worse survival (Figures 5B and 5C).  Localized pre-surgical patients with less than 
5.0 x 10^9 exosomes per mL plasma had a median survival of 1040 days compared to 421 days 
for those with higher exosome concentrations (P=0.047).  Similarly, metastatic patients with less 
than 5.0 x 10^9 exosomes per mL plasma had a median survival of 479 days compared to 97 
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days for those with higher exosome concentrations (P=0.015).
 
Figure 4: Profiling of exosomal physical characteristics  
A. Transmisison and scanning electron microscopy of exosomes demonstrates a bilipid 
membrane falling within the size range of a define exosome. B, C. Average particle size oserved 
based on Zetaview nanoparticle tracking analysis. D. Flow cytrometry demonstrating presence 
of known surface exosome marker, CD63, compared to isotype control. E. Western blot analysis 
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Figure 5: Liquid biopsy Kaplan-Meier curves 
 (A) Stratification of exoKRAS at a mutant allele frequency of 1% was associated with disease 
free survival in patients with localized disease who were treatment naïve at the time of blood draw 
(n = 13) with a median survival of 441 days compared to 127 days (P = 0.031). Two treatment 
naïve patients with no KRAS mutant droplets were excluded from this survival analysis to account 
for the possibility that they have a KRAS mutation that is not a target of the KRAS multiplex 
ddPCR kit used. (B and C) Exosome concentration of 5 × 109 per ml of plasma was associated 
with overall survival in treatment naïve blood draws in patients with (B) localized disease 
(n = 15, median survival 616 versus 233 days, P = 0.048) and (C) metastatic disease 
(n = 12, median survival 479 versus 97 days, P = 0.015). 
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Liquid biopsy detects exoDNA KRAS mutants by digital PCR 
In the discovery cohort, ddPCR analysis of exoDNA detected KRAS mutations in 66.7% (22/33), 
80% (12/15) and 85% (17/20) of localized, locally advanced, and metastatic PDAC patients, 
respectively, and in 7.4% (4/54) of controls (Table 1). For predicting PDAC status, the resultant 
sensitivity and specificity are 75.4% and 92.6% respectively.  Positive mutant KRAS status from 
exoDNA was significantly associated with early stage PDAC when comparing patients with 
localized disease to healthy individuals (Fisher’s exact test P<0.001), where an individual with 
positive KRAS status is 8.17 times (95% CI: 2.46 to 35.58) more likely to have early stage 
pancreatic cancer than to be cancer free.  Further, compared to localized pre-resected patients 
with a mutant KRAS detection rate of 66.7%, in a similar cohort of 20 localized PDAC patients 
with blood sampled after resection, mutant detection rate was much lower at 5%.  Mutant KRAS 
status was significantly associated with pre-resection blood sampling (Fisher’s exact test, 
P<0.001).  Of note, healthy controls had a mutant detection rate of 7.4% (4/54).  KRAS mutant 
status in the healthy controls was associated with increased age (mean age of 75 years in mutant 
KRAS individuals versus 64 years in wild-type KRAS individuals; Wilcoxon rank sum test 
P=0.004).   
Table 3: Liquid biopsy mutant call rates among patient populations  
Stage of disease  
cfKRAS mutant call rate 
(%)  
exoKRAS mutant call rate 
(%)  
Discovery cohort      
 Healthy  8/54 (14.8)  4/54 (7.4)  
 Localized  15/33 (45.5)  22/33 (66.7)  
 Localized 
postsurgical  0/20 (0)  1/20 (5)  
 Locally advanced  4/13 (30.8)  12/15 (80)  
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Stage of disease  
cfKRAS mutant call rate 
(%)  
exoKRAS mutant call rate 
(%)  
 Metastatic  11/19 (57.9)  17/20 (85)  
Validation cohort      
 Healthy  –  17/82 (20.7)  
 Localized  –  17/39 (43.6)  
 
In the validation cohort, 44% (17/39) of early stage pancreatic cancer patients tested positive for 
KRAS compared to 20% (17/82) of healthy individuals, confirming that KRAS positivity is 
associated with pancreatic cancer (Fisher's exact test, P=0.0163).  An individual with KRAS 
positivity was 2.96 times (95% CI: 1.29 to 6.76) more likely to have pancreatic cancer than to be 
healthy.  Unlike with the discovery cohort, no association of age with mutant exoKRAS status 
was found in the healthy controls. 
 
Mean KRAS mutation allele frequencies were higher in metastatic compared to localized 
samples (mean of 10.09% versus 2.7% respectively; Wilcoxon rank sum test P=0.0109).  
 
Stratification of localized patients based on a pre-surgery exoKRAS MAF threshold of 1% was 
associated with disease-free survival following resection, (Figure 2A), with a median disease-
free time of 441 vs 127 days for patients with less than 1% MAF compared to those with more 
than 1% MAF (P=0.031; Figure 2A).  In addition, greater than a 1% MAF was a significant risk 
factor impacting disease-free survival (RR, 4.68; 95% CI, 1.014-21.61).   While a slight, yet 
statistically significant positive correlation existed between KRAS MAF and CA19-9 levels 
(P=0.019, r=0.303), only KRAS MAF was associated with disease-free survival.  Cox proportional 
hazard analyses were also performed on locally advanced and metastatic patients but no clinical 
factors were found to be significantly associated with overall or progression-free survival.  
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Performance of cfDNA in liquid biopsy 
In the discovery cohort, mutant cfKRAS was detected in 14.8% (8/54), 45.5% (15/33), 30.8% 
(4/13), and 57.9% (11/19) of healthy controls, localized, locally advanced, and metastatic 
patients.  Of these positive cfDNA calls respectively, 12.5% (1/8), 73.3% (11/15), 100% (4/4) and 
100% (11/11) were also called positive through exoDNA.  As opposed to the exoDNA results, 
KRAS positive status in healthy control cfDNA was not associated with increasing age (data not 
shown).  In the metastatic group, the presence of mutant KRAS cfDNA suggested worse overall 
survival (median survival of 115 days compared to 506 days for mutant KRAS negative patients), 
but this was not statistically significant (P=0.107). 
  
Discussion: 
Exosomes, which have been shown to harbor DNA (70, 72), are the product of specific 
biogenesis pathways and are shed from viable cells by the tens of millions into circulation.  
Conversely, traditional cfDNA is derived from apoptosis and necrosis of tumor cells, which are 
characteristic of later stage disease (141). It may thus be possible that exoDNA is a significant 
contributor of the DNA in circulation in patients of earlier clinical stage, before cell death and 
tumor necrosis begin to occur.  In this context, the origin of the circulating DNAs may explain why 
the detection rate for early stage patients in this study was slightly higher with exoDNA than that 
previously described for cfDNA, but also why the identification of late stage patients was 
concordant (42).    
 
Most encouraging is the observation of a precipitously lower detection rate in the localized pre 
and post-resection cohorts, from 66% to 5%.  With mutant KRAS being a surrogate for tumor-
specific DNA, and resection for curative intent aimed at removing the entirety of the localized 
disease, pre- and post- procedure liquid biopsies may have utility in determining the early 
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success of resection.  It is important to mention though, that the lower KRAS detection may be 
an overall marker of response to any therapy, and not just surgery alone.  We are unable to draw 
such conclusions from this data set as time points before and after other treatment modalities 
are not available for our cohorts. 
  
In this study, exoKRAS mutant allele frequency, but not CA19-9, was associated with disease 
free survival in localized disease.  Whereas presence or absence of cfDNA and overall amount 
of DNA has previously been used for stratification, we did not identify such a clinical correlation.  
In a tumor where oncogenic KRAS gene mutations are believed to be near ubiquitous, to the 
best of our knowledge, this is the first time KRAS mutant allele frequency in exoDNA has been 
used for prognostic stratification.   While a 1% mutant KRAS fractional abundance was identified 
in our discovery cohort as being informative towards disease-free survival, further validation is 
warranted for any such proposed cancer biomarker (142). 
   
CfDNA was detected between 30.8-57.9% across stages, which is concordant with the findings 
of earlier studies (42).  No studies to date have described the detection rate of KRAS mutant 
alleles within exosomes across a series of PDAC patients across all stages, nor compared these 
directly with cfDNA.  For this reason, we performed a parallel analysis of liquid biopsy for cfDNA 
KRAS mutations from plasma samples from the same patients to serve as a comparison, in 
addition to historical cfDNA detection rates in the literature.  In our study, rates of detection of 
KRAS mutants in exosomes were superior to cfDNA across all stages.  Of particular interest is 
our finding that exoDNA revealed a greater detection of patients with localized disease than 
previously observed using a highly sensitive method of detection (42).  Validation is warranted, 
but this finding has potential ramifications for liquid biopsy based diagnostics, especially in 
tumors where specific mutant detection yields the opportunity for treatment with targeted therapy. 
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Identification of KRAS mutations in 7.4% of exoDNA and 14.8% of cfDNA healthy controls in the 
discovery cohort and in 20.7% in the exoDNA of the validation cohort was an unexpected finding 
with potential implications for using liquid biopsies as a screening tool.  Indeed a survey of the 
literature shows that KRAS mutations in apparently healthy samples have been previously 
described (See Supplemental table 1) both in a liquid biopsy setting, and in autopsy series (in 
non-cancerous pancreata).  It is important to mention that in an era where highly sensitive 
detection techniques are now available, detection rates for “background” oncogenic mutations 
are likely to increase.  It is possible that the finding of such mutations describe a pre-malignant 
process within the pancreas or a KRAS-mediated malignancy outside the pancreas.  Perhaps, 
these mutations accumulate in organs with increasing age but the rate at which these mutations 
progress to invasive cancer is unknown.  Mutant KRAS findings in the normal controls of the 
discovery cohort suggests that accumulation of driver mutations may be an age-related 
phenomena as recently described by Krimmel and colleagues for TP53 mutations in control 
patients (143).  However, no association of age and mutant KRAS status in healthy controls was 
found in our validation cohort.  For purposes as an early cancer-screening diagnostic, the 
specificity of our approach would need to be improved possibly by requiring a minimum KRAS 
mutation allele frequency to make a positive mutant status call, which is the focus of continued 
work.   Additional biomarkers, such as other cancer DNA mutations or protein biomarkers could 
also be added into the screening model to increase the sensitivity to make it clinically useful. 
 
In the setting where the patient’s cancer status is known a priori, then the utility of a liquid biopsy 
lies in the ability to observe serially the response of genetic mutations as a form of personalized 
biomarkers to therapy. It is necessary to consider that KRAS mutations as a PDAC biomarker 
may be of particular value in terms of assessing response to therapy in those 5-20% of patients 
who do not express the Sialyl Lewis-A, or CA 19-9 antigen (144), and furthermore in those 
patients in whom CA-19-9 becomes unreliable in the frequent setting of obstructive jaundice.  
Additionally, the radiologic appearance and response of PDAC to therapy on cross-sectional 
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imaging is negligible to the point that non-progression on therapy has become a qualifier to 
proceed to surgery in borderline-resectable patients (145). 
 
Conclusion 
In this study, exoDNA outperformed cfDNA for the detection of mutant KRAS in PDAC patients.  
Further, the exoDNA detection rate of patients with early stage tumors is greater than that 
previously reported.  However, a substantial portion of healthy control patients also exhibited 
KRAS mutations.  This suggests that follow-up studies more generally focused on uncovering 
the prevalence of known cancer mutations (in addition to KRAS mutations) in healthy individuals 
are needed to try to put these mutations into biological context and to ultimately understand their 
clinical repercussions.  In the context of liquid biopsy, the application for ultrasensitive 
identification of a single genetic mutation as a predictor for PDAC may be limited. 
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Abstract  
Background and Aims: We aim to investigate the clinical utility of liquid biopsies, specifically 
circulating tumor DNA (ctDNA) and exosomal DNA (exoDNA) in localized and metastatic 
pancreatic cancer.   
 
Methods: We have utilized liquid biopsies to measure KRAS mutant allele frequency (MAF) by 
droplet digital PCR (ddPCR) in paired exoDNA and ctDNA in a prospective cohort of 194 
localized and metastatic pancreatic cancer patients, comprising 425 blood samples.  
 
Results: Concordance rates of KRAS mutations present in tissue and detected in liquid biopsies 
was 95.5% in 34 patients. Among 34 potentially resectable patients, an increase in exoDNA 
following neoadjuvant therapy was significantly associated with progressive disease (p=0.003), 
while profiling of ctDNA in this cohort did not reveal significant correlations to outcomes. 
Metastatic patients (n=104) with detectable ctDNA at baseline status experienced shorter 
progression free (PFS) (HR 1.8, 95% CI 1.1 – 3.0, p=0.019), and overall survival (OS) (HR 2.8, 
95% CI 1.4-5.7, p=0.0045) on univariate analysis. On multivariate analysis, exoDNA MAF ≥5% 
emerged as a significant predictor of shorter PFS (HR 2.28, 95% CI 1.18-4.40, p=0.014) and OS 
(HR 3.46, 95% CI 1.40-8.50, p=0.007). A multi-analyte approach revealed detection of both 
ctDNA and exoDNA MAF ≥5% at baseline treatment naïve status as a significant predictor of OS 
(HR 7.73, 95% CI 2.61-22.91, P=0.00002) on multivariate analysis. Further, on longitudinal 
monitoring in 34 metastatic patients, an exoDNA KRAS MAF peak  ≥1% was significantly 
associated with radiological progression (p=0.0003).  
 
Conclusions: In a large clinical evaluation of pancreatic cancer, we demonstrate how the use 
of exoDNA and ctDNA provide complementary strategies for prognostication and therapeutic. 
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Introduction 
Although rare, pancreatic ductal adenocarcinoma (PDAC) has recently become the third leading 
cause of cancer related deaths with projections of it rising to the second leading cause of cancer 
deaths within the next decade (1).  While surgical resection provides a potential curative option 
in PDAC, only a minority of patients (<15%) will be diagnosed with disease that is amenable to 
surgery, and even in this subset of patients, 5 year overall survival (OS) rates remain below 30%.  
Neoadjuvant therapies are increasingly being adopted to enhance local disease control in 
resectable patients. As most PDAC patients present with surgically unresectable tumors, current 
therapeutic options in this patient population has resulted in modest benefits in OS with no means 
to personalize therapy currently.  Among both localized and metastatic patient populations, there 
still remains a significant unmet need in developing more effective strategies for therapeutic 
stratification and management. 
 
The use of blood based biomarkers for cancer diagnosis and therapeutic stratification has gained 
significant traction in cancer in the form of circulating proteins, RNA, and DNA.  Specifically, 
circulating tumor DNA (ctDNA) detection in the blood of breast, colorectal, and lung cancer 
patients, amongst others, has shown clinical relevance in identifying patient relapses (146-150).  
In the context of PDAC, the use of ctDNA as a clinically significant biomarker has been 
inconsistent in regards to its prognostic and predictive potential  (42, 82, 151-153).  Additional 
sources of DNA and RNA in circulation have been recently identified in the form of microvesicles 
known as exosomes (154).  Previous studies have shown the utility of profiling the genomic 
content of exosomes (exoDNA) as a surrogate for the mutational landscapes of established 
cancers, and for early detection (70, 74, 82). These 40-150nm lipid bilayer membrane bound 
vesicles are believed to form protective barriers of nucleic acid material from nuclease induced 
degradation in the plasma, thus allowing for the native material to exist in a high molecular weight 
format compared to ctDNA which is mostly found at 170bp size.  Importantly, this could allow for 
greater resolution and sensitivity of  molecular profiling of high quality DNA material. 
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In this study, we aimed to compare the utility of tumor monitoring in localized and metastatic 
PDAC patients using paired exoDNA and ctDNA, to determine how they may be used in a 
complementary manner for prognostication and therapeutic stratification. We performed 
longitudinal collection in a large prospective cohort of PDAC patients with localized and 
metastatic cancer, such that the dynamics of KRAS mutation detection in circulation could be 
correlated with disease progression and compared with standard readouts, such as imaging and 
CA19-9.  To our knowledge, this study represents the first comprehensive comparison of these 
liquid biopsy compartments in the context of clinical utility. Additionally, we believe the 
longitudinal aspects of this study have implications for potential real-time therapeutic stratification 
of PDAC patients.  
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Study Design 
Patients who were clinically and histologically confirmed as localized or metastatic pancreatic 
adenocarcinoma, defined by American Joint Committee on Cancer guidelines, were enrolled in 
this longitudinal cohort study. Metastatic disease was based on surgical or radiologic 
confirmation. A total of 194 patients were recruited at MD Anderson Cancer Center through 
informed consent following institutional review board (IRB) approval (PA14-0552 and PA11-
0670) and treated between 04/07/2015 to 10/13/2017 (Figure 6). Of these, 104 patients 
presented at baseline treatment naïve status with metastatic PDAC. If receiving first-line therapy, 
treatment naïve patients underwent pre-treatment CT imaging and followed every 2-3 months 
with restaging imaging after initiation of chemotherapy. Progression in all patients was 
determined based on routine clinical evaluation by a blinded board certified radiologist based on 
RECIST 1.1 criteria of CT imaging. Progression free survival was defined by the time from start 
of first line therapy to progression based on CT restaging imaging. 
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Results 
Characteristics of patients undergoing liquid biopsies 
Study overview and patient stratification are presented in, Table 4.  A total of 318 blood samples 
from 123 metastatic and 107 blood samples from 71 localized resectable patients were profiled 
using ddPCR. Median follow-up time for all patients was 187 days. ExoDNA and ctDNA profiled 
at baseline treatment naïve status revealed KRAS mutation detection rates of 61% and 53%, 
respectively in metastatic patients and 38% and 34%, respectively in localized disease patients 
(Figure 7A, B).  To determine prevalence of circulating mutational events in other pancreatic 
diseases, an additional 37 patients with pancreatic lesions were evaluated for KRAS mutations 
in exoDNA and ctDNA.  Mutation detection rates were 12% (3/25) and 16% (4/25) for pancreatic 
cysts, 25% (3/12) and 17% (2/12) for non-neoplastic pancreatic disease, within exoDNA and 
ctDNA respectively.   
Figure 6: Patient population cohorts for baseline prognostication and longitudinal follow-up 
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When comparing all patient populations, those with metastatic disease had significantly greater 
circulating mutant allelic fraction (MAF) of KRAS compared to localized disease and panceatic 
cyst patients (Figure 7C).  Patients with localized disease had significantly greater MAF 
compared to panceatic cyst patients. We also determined gold standard validation of 
concordance rates between exoDNA and ctDNA with tumor tissue for KRAS mutation detection 
using ddPCR (Table 5). Concordance among 22 surgically resected primary pancreatic tumors 
was 95.5% and 68.2% for exoDNA and ctDNA respectively, while concordance from 12 samples 
derived by fine needle aspirates was 83.3% and 66.8% for exoDNA and ctDNA respectively. 
Fisher Test
KRAS	≥	5 KRAS	<	5 KRAS	>	0 KRAS	=	0 exoDNA ctDNA
Average 64.4 63.2 65 63.1 67.1
Median 65 60 65 62 67
Range (39-86) (45-86) (39-84) (39-86) (46-84)
P-value 0.135 0.8345
Male 60	(57.7) 23	(22.1) 37	(35.6) 41	(39.4) 19	(18.3) CI 0.817 5.7 0.447 2.758
Female 44	(42.3) 10	(9.6) 34	(32.7) 29	(27.9) 15	(14.4) Odds Ratio 2.1 1.11
P-value 1 0.7144
Hispanic	or	Latino 9	(8.7) 3	(2.9) 6	(5.8) 7	(6.7) 2	(1.9) CI 0.164 5.49 0.312 18.422
Not	Hispanic	or	Latino 95	(91.3) 30	(28.8) 65	(62.5) 63	(60.6) 32	(30.8) Odds Ratio 1.092 1.769
P-value 0.8814 0.795
Asian 3	(2.9) 1	(1) 2	(1.9) 2	(1.9) 1	(1)
Black	or	African-American 11	(10.6) 4	(3.8) 7	(6.7) 9	(8.7) 2	(1.9)
Caucasian	(White) 85	(81.7) 26	(25) 59	(56.7) 56	(53.8) 29	(27.9)
Native	and	Other 5	(4.8) 2	(1.9) 3	(2.9) 3	(2.9) 2	(1.9)
P-value 0.4439 0.2999
Head	of	Pancreas 47	(45.2) 12	(11.5) 35	(33.7) 31	(29.8) 16	(15.4)
Tail	of	Pancreas 25	(24) 10	(9.6) 15	(14.4) 18	(17.3) 7	(6.7)
Body	of	Pancreas 30	(28.8) 11	(10.6) 19	(18.3) 20	(19.2) 10	(9.6)
Neck	of	Pancreas 2	(1.9) 1	(1) 1	(1) 0	(0) 2	(1.9)
P-value 0.02515 0.04322
Liver 82	(78.8) 31	(29.8) 51	(49) 60	(57.7) 22	(21.2)
Lung 11	(10.6) 0	(0) 11	(10.6) 6	(5.8) 5	(4.8)
Peritoneal 10	(9.6) 2	(1.9) 8	(7.7) 4	(3.8) 6	(5.8)
Ovarian 1	(1) 0	(0) 1	(1) 0	(0) 1	(1)
P-value 0.00312 0.0004775
Death	PC 32	(30.8) 16	(15.4) 16	(15.4) 24	(23.1) 8	(7.7)
Death	other 2	(1.9) 18	(17.3) 18	(17.3) 10	(9.6) 26	(25)
Alive 58	(55.8) 11	(10.6) 47	(45.2) 36	(34.6) 22	(21.2)
Lost	to	Follow-up 11	(10.6) 4	(3.8) 7	(6.7) 7	(6.7) 4	(3.8)
P-value 0.5543 0.5641
Lifelong	Non-smoker 53	(51) 14	(13.5) 39	(37.5) 33	(31.7) 20	(19.2)
Current	reformed	smoker 29	(27.9) 10	(9.6) 19	(18.3) 20	(19.2) 9	(8.7)
Current	smoker 6	(5.8) 2	(1.9) 4	(3.8) 4	(3.8) 2	(1.9)
Not	Available,	EMR 16	(15.4) 7	(6.7) 9	(8.7) 13	(12.5) 3	(2.9)
P-value 0.5591 0.3651
No 46	(44.2) 14	(13.5) 32	(30.8) 32	(30.8) 14	(13.5)
Yes 43	(41.3) 14	(13.5) 29	(27.9) 28	(26.9) 15	(14.4)
Denied 8	(7.7) 4	(3.8) 4	(3.8) 7	(6.7) 1	(1)
Not	Available-EMR 7	(6.7) 1	(1) 6	(5.8) 3	(2.9) 4	(3.8)
P-value 0.4924 0.4331
No 64	(61.5) 21	(20.2) 43	(41.3) 44	(42.3) 20	(19.2)
Long-standing	type	2	diabetes 25	(24.0) 7	(6.7) 18	(17.3) 14	(13.5) 11	(10.6)
Newly-diagnosed	diabetes-within	1	 7	(6.7) 4	(3.8) 3	(2.9) 6	(5.8) 1	(1)
Long-standing	type	1	diabetes 1	(1) 0	(0) 1	(1) 1	(1) 0	(0)
Not	Available,	EMR 7	(6.7) 1	(1) 6	(5.8) 5	(4.8) 2	(1.9)
P-value 0.5506 0.5492
No 92	(88.5) 29	(27.9) 63	(60.6) 59	(56.7) 33	(31.7)
Not	Available-EMR 9	(8.7) 4	(3.8) 5	(4.8) 8	(7.7) 1	(1)
Yes 3	(2.9) 0	(0) 3	(2.9) 3	(2.9) 0	(0)
Family	history	of	cancer 71	(68.3) 21	(20.2) 50	(48.1) 45	(43.3) 26	(25)
Familial	PC 6	(5.8) 2	(1.9) 4	(3.8) 4	(3.8) 2	(1.9)
P-value 0.03888 0.2846
Progressed 66	(63.5) 53	(51) 13	(12.5) 47	(45.2) 19	(18.3) CI 0.993 0.635 4.048
No	Progression 38	(36.5) 23	(22.1) 15	(14.4) 23	(22.1) 15	(14.4) Odds Ratio 2.632 1.606
Smoking	History













Table 4: Patient characteristics and stratification 
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Figure 7 Mutant KRAS detection characteristics in a prospective cohort of tumor and benign 
pancreatic disease 
Venn diagram of detection rates of codon 12/13 mutant KRAS by ddPCR among (A) 102 
metastatic and (B) 66 localized PDAC patients with matched exoDNA and ctDNA analysis. (C) 
MAF of KRAS mutations detected through ddPCR in exoDNA and ctDNA among baseline 
treatment naïve localized and metastatic patients, and patients with benign pancreatic cysts and 
non-neoplastic pancreatic disease. Greater median MAF in exoDNA compared ctDNA in 
metastatic patients trended towards significance (p = 0.05), paired analysis performed by 
Wilcoxon test. Those patients with metastatic disease had higher KRAS MAF in both exoDNA 
(p<0.0001) and ctDNA (p=0.0004) when compared to patients with localized disease, by Mann-
Whitney test. (p<0.05*, p<0.01**, p <0.001***, p<0.0001****) 
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Table 5 Concordance rates of tumor tissue and liquid biopsy mutant KRAS detection 
 




Sample	 exoDNA cfDNA Tissue	KRAS
MK238 	-	 	-	 	-	
MK240 	-	 	-	 	-	
MK248 + 	-	 	+
MK257 + + 	+	
MK259 + + 	+	
MK272 	+	 	- 	+	
AM62 + + 	+
AM88 	-	 	-	 	-	
MK44 + 	-	 	+	
MK99 	-	 - 	-	
MK116 	-	 	-	 		+		
MK127 	-	 	-		 	-	
MK160 	-	 	-	 	-	
MK191 + 	-	 	+	
MK212 	- 	-	 	-	
MK217 + + 	+	
MK230 + 	-	 	+	
MK152 - - 	-		
MK227 + - 	+	
AM95 	-	 	-	 	-	
MK307 	- 	- 	-
DH14 	+	 	+	 	+	
ExoDNA ctDNA
Sensitivity 91.67% Sensitivity 50%
Specificity 100% Specificity 100%
PPV 100 PPV 100
NPV 90.91	(CI	60.49	-	98.49) NPV 62.50	(48.63	-	74.59)




Sample	 exoDNA cfDNA Tissue	KRAS
WB02 	- + 	+	
MK151 + + 	+	
MK229	 	-	 	-	 	-	
MK10 + - 	+
MK17 + + 	-
MK27 + + 	+	
GV79 	+	 + 	+
BW13 + + +
WB27 + - +
AM74 + + +
MK12	 	+ 	- 	+	
MK42 	+ 	+	 	+	
ExoDNA ctDNA
Sensitivity 90.00% Sensitivity 50%
Specificity 50% Specificity 90%
PPV 90	(CI	68.91	-	97.34) PPV 85.71	(CI	46.21	-	97.67)	
NPV 50	(CI	8.96	-	91.04) NPV 60.00	(45.09	-	73.26)
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Serial liquid biopsies in localized PDAC patients receiving neoadjuvant therapy are 
predictive of eventual surgical resection 
A total of 34 PDAC patients with localized disease were serially monitored during neoadjuvant 
therapy, comprising 68 cumulative blood draws taken at baseline and after the completion of 
neoadjuvant therapy (Table 6).  Kinetics of circulating KRAS mutational burden were then 
measured in exoDNA and ctDNA using ddPCR.  Mutant KRAS was detected in 41% (14/34) and 
32% (11/34) of patients in exoDNA and ctDNA, respectively at baseline.  Among the patients 
monitored, 50% (17/34) underwent subsequent surgical resection given an absence of  
disease progression, compared to 50% who experienced disease progression, primarily 






Age (year) 64.9±9.1 65.8±11.1 64.4±8.3 0.332 0.743
Primary tumor size 30.2±9.1 30.5±11.6 30.0±8.0 0.122 0.904
N (%) N (%) N (%)
Gender
  Male 20 11 9  0.73 a
  Female 14 6 8
Tumor location
  Head 27 13 14  1.000 a
  Body or Tail 7 4 3
Neoadjuvant 
Chemotherapy
GEM + ABR 18 10 8 0.49 a
FOLFIRINOX 16 7 9
Neoadjuvant XRT
  30Gy 11 5 6 1.000 a
  50.4Gy 15 6 9
N/A 8 6 2
Radiosensitizing 
Agent
Capecitabine 22 10 12 0.61 a
Gemcitabine 4 1 3
N/A 8 6 2
Change of ExoDNA 
KRAS
No decrease 21 16 5  0.0002 a
Decrease 13 1 12
Change of cfDNA 
KRAS
No decrease 25 11 14  0.44 a
Decrease 9 6 3
Change of CA 19-9 
  Increase 9 8 1              0.003 a





Table 6: Clinical characteristics of patients receiving neoadjuvant chemotherapy 
  67 
MAF from baseline at the completion of neoadjuvant therapy was significantly correlated with 
surgical resection, while the reverse was true for patients who did not emerge as surgical 
candidates (OR 38.4, CI 3.95-373.3, p=0.0002) (Figure 8A, B).  Specifically, among patients who 
underwent resection, 71% (12/17) experienced a decrease in exoKRAS MAF from baseline 
treatment naïve values, while in those patients who did not, 16/17 (94%) saw an increase or no 
change in KRAS MAF in exoDNA from baseline status.  As one example, in an index case, a rise 
in KRAS MAF in exoDNA suggested progressive disease, though that was initially not detectable 
by CA19-9 or CT imaging.  On laparotomy, CT-occult omental metastasis was found resulting in 
an aborted resection.  This correlation between changes in KRAS MAF and resectability was, 
however, not seen with ctDNA.  After eliminating those patients who were considered as non-
expressors of CA19-9 (values below 37 U/ml), changes in CA19-9 were also significantly 
correlated to those patients likely to undergo surgery (OR 28.0, CI 2.65-295.9, p=0.003). Among 
three patients where no detectable exoKRAS mutant was found, CA19-9 was able to predict 




























Figure 8 Liquid biopsy tumor monitoring of patients receiving neoadjuvant therapy 
(A) Tumor monitoring before and after neoadjuvant chemoradiation in a patient 
experiencing progression undetectable by CA19-9 (blue line) or radiological based 
RECIST 1.1 (black line). (B) MAF kinetics of exoDNA and ctDNA before and after 
neoadjuvant therapy shows a significant correlation between a rise or no change in 
exoDNA MAF and progression (OR 38.4, CI 3.95-373.3, p=0.0002). No significant 
correlation was detectable by ctDNA. Changes in CA19-9 from baseline were also 
significantly associated to progressive disease (OR 28.0, CI 2.65-295.9, p=0.003).   
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Clinical correlates of liquid biopsies at presentation in metastatic PDAC patients 
Among metastatic PDAC patients, clinical characteristics at the time of presentation were 
grouped according to exoDNA and ctDNA status are shown in Table 4.  There was no significant 
association between KRAS MAF in exoDNA and ctDNA, and presenting characteristics.  Overall, 
66 (63%) had experienced radiologic progression and 69 (67%) were still alive at mila last follow-
up date.  Patients who experienced progression during serial monitoring or succumbed to 
disease had higher KRAS MAF in exoDNA at presentation (Wilcoxon signed-rank tests, p=0.03 
and p=0.01, respectively) when compared to those that had not progressed (Figure 9).  CtDNA 
tumor burden, as measured by KRAS MAF at presentation, was also significantly associated with 
survival (p=0.03) (Figure 9B).  Patients with liver metastatic lesions had a significantly greater 
KRAS MAF in exoDNA and ctDNA, compared to patients with isolated lung and peritoneal lesions 
(p=0.04) (Figure 10A-B).  This correlation was likely impacted by the fact that patients with 
metastasis to the liver have larger volume of lesions compared to those with isolated lung and 
peritoneal metastases (Figure 10C).  In fact, on linear regression analysis, exoDNA and ctDNA 
KRAS MAF at presentation was significantly correlated with tumor size as measured by total sum 
of lesion diameters (p=0.035 and p=0.0008, respectively) (Figure 11).  Additionally, patients with 
progressively worse ECOG performance status harbored significantly greater KRAS MAF 















Figure 9 Correlates of survival and  KRAS MAF at baseline treatment naïve 
status. 
A. Median MAF of exoKRAS in metastatic patients is significantly greater in those 
patients that have progressed (p = 0.03) and are deceased compared (p=0.01) to 
those that are not. B. Median MAF of ctKRAS is significantly greater in those 
patients that are deceased compared (p=0.03) to those that are not, by Mann-
Whitney test. All axis have been scaled to log10 for visual representation.   
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Figure 10 Distribution of exoKRAS, ctKRAS, and SLD stratified against type of metastasis 
Boxplots of the distributions. Log10( x + 1)  was used to transform the KRAS results. X + 1 was used to 
keep KRAS MAF values at 0. The Wilcoxon test was used to compare between two subsets and the 
Kruskal-Wallis was used to compare between all three. A. exoKRAS MAF (N = 103) plotted against 
metastasis type. Median and range for Liver, Lung and Peritoneal Metastasis were 1.463 (0-59.091), 0 
(0-1.763), 0 (0-25.358) respectively. P-value between pairs of Liver and Lung, Liver and Peritoneal, and 
Lung and Peritoneal were 0.028, 0.15, 0.72 respectively. P-value for all three was 0.044. B. exoKRAS 
MAF (N = 100) plotted against metastasis type. Median and range for Liver, Lung and Peritoneal 
Metastasis were 0.760 (0-60.969), 0 (0-0.327, 0 (0-21.664) respectively. P-value between pairs of Liver 
and Lung, Liver and Peritoneal, and Lung and Peritoneal were 0.0021, 0.017, 0.58 respectively. P-
value for all three was 0.00084. C. SLD (Sum of Longest Diameters) (N = 102) plotted against 
metastasis type. Median and range for Liver, Lung and Peritoneal Metastasis were 77.5 (21-200), 61 
(43-111, 61 (40-181) respectively. P-value between pairs of Liver and Lung, Liver and Peritoneal, and 
Lung and Peritoneal were 0.17, 0.56, 0.84 respectively. P-value for all three was 0.36. 
 
















Figure 11 Trend between KRAS MAD and SLD 
Linear regressions on between both exoKRAS and ctKRAS and SLD. (A) ExoKRAS 
modeled by f(x) = 1.336 + 0.07376x. P-value = 0.0353. R2 = 0.04353, (B) ctKRAS modeled 
by f(x) = -3.154 + 0.1145x. P-value = 0.000848. R2 = 0.1089 
 
















Figure 12 Distribtion of exoKRAS and cfKRAS stratified for ECOG performance 
status.  
Boxplots of the distributions. Log10( x + 1)  was used to transform the KRAS results. X + 
1 was used to keep KRAS MAF values at 0. The Wilcoxon test was used to compare 
between two subsets and the Kruskal-Wallis was used to compare between all 
categories. 
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Prognostic impact of liquid biopsy parameters at presentation in metastatic PDAC 
patients  
To avoid confounding effects of chemotherapy on exoDNA and ctDNA kinetics, we performed 
subset analysis on 104 metastatic patients who were treatment naïve at the time of presentation.  
An optimal threshold for ctDNA was assessed by receiver operating curve (ROC) analysis with 
the optimal cutoff achieving a sensitivity and specificity of 60% and 54% for OS, and 53% and 
50% PFS, respectively.  As previously described in other tumor types, the presence and absence 
of detectable ctDNA (i.e., any mutant KRAS on ddPCR) was significantly associated with patient 
outcomes (146, 149).  For example, any detectable ctDNA was associated with significantly 
shorter PFS (log-rank test; HR 1.93, 95% CI 1.15-3.22, p=0.012) with a median PFS of 118 
versus 321 days (for detection versus no detection, respectively, (Figure 13B). Detectable 
ctDNA also showed shorter OS (HR 2.36, 95% CI 1.16-4.79, p=0.018) with a median OS of 258 
vs 440 days (detection and no detection, respectively, (Figure 13B).  In the context of exoDNA, 
an optimal exoKRAS MAF was determined to be 5%, achieving the optimal cutoff by ROC 
analysis with a sensitivity and specificity of 51% and 85% for OS, and 89% and 36% for PFS 
respectively.  Using this threshold of 5% KRAS MAF, patients with higher than 5% KRAS MAF 
were significantly associated with reduced PFS (HR 4.78, 95% CI 2.47-9.26, p<0.0001) and OS 
(HR 7.31, 95% CI 3.15-17.00, p<0.0001) on Kaplan-Meier analysis (Figure 13A).  Similarly, 
survival analyses of the standard clinical biomarker CA19-9 (Figure 14) demonstrated that 
patients with a CA19-9  ≥ 300  at treatment naive presentation had worse OS (p=0.023), with 
PFS trending towards significance (p=0.06). 
 
  75 
Using a Cox regression model (Table 7), univariate analysis revealed KRAS MAF  ≥5% in 
exoDNA (HR 3.5, 95% CI 2.1 – 5.9, p<0.0001) and any ctDNA detection (HR 1.8, 95% CI 1.1 – 
3.0, p=0.019), were significantly associated with shorter PFS. On multivariate analysis, exoKRAS  
≥5% remained the only significant predictor of PFS (HR 2.28, 95% CI 1.18-4.40, P=0.014).  
Combining KRAS MAF  ≥5% in exoDNA or ctDNA detection with a CA19-9 ≥300 did not reveal 
an increase in predictive significance of these biomarkers for poorer PFS. 
 
Figure 13 Kaplan-Meier curve stratification of baseline treatment naïve metastatic 
patients.  
(A) Patients with exoKRAS ≥5% experienced worse PFS (median 71 vs 200 days) and OS 
(median 204 vs 440 days). Detection of ctDNA was significantly associated with worse PFS 
(median 118 vs 231 days) and OS (258 days vs 440 days). 
 












Figure 14 Kaplan Meier curve stratification of baseline treatment naïve patients 
based on CA19-9. 
(Top) Patients with CA19-9  ≥300  experienced worse OS (median 204 vs 264 days, p 
= 0.023), (Bottom) but not significantly worse PFS (p=0.06).  
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 beta  HR (95% CI for HR)  wald.test  p.value
exoKRAS >5% 1.2    3.5 (2.1-5.9) 22 3.5E-06
ctDNA Detection 0.59 1.8 (1.1-3) 5.5 0.019
Age -0.0027      1 (0.97-1) 0.04 0.83
Gender (Male v Female) 0.45    1.6 (0.94-2.6) 3 0.084
ECOG (0 v 1) 0.6766 1.5 (0.72-3.04) 2.79 0.289
ECOG (0 v 2) 0.502 2.0(0.79-5.03) 2.79 0.145
ECOG (0 v 3) 0.442 1.51(0.40-5.68) 2.79 0.541
Regimen: GEM v FOLFIRINOX 0.53    1.7 (0.99-2.9) 3.7 0.054
Metastatic site: Liver v Lung -0.775 0.4605 (0.2040-1.039) 5.29 0.0619
Metastatic site: Liver v Peritoneal -0.719 0.4873 (0.2043-1.162) 5.29 0.1051
CA19-9 > 300 0.41    1.5 (0.89-2.6) 2.4 0.12
Multi-Analyte Analysis
exoKRAS >5% and CA19-9 > 300 1.2   3.2 (1.9-5.5) 18 2.00E-05
exoKRAS >5% or CA19-9 > 300 0.64   1.9 (1.1-3.3) 4.7 0.03
ctDNA Detection and CA19-9 > 300 0.75   2.1 (1.3-3.5) 8 0.0048
ctDNA Detection or CA19-9 > 300 0.52   1.7 (0.89-3.2) 2.6 0.11
exoKRAS >5% + ctDNA Detection + CA19-9 > 300 1.4 3.9 (2.2-7.1) 21 5.20E-06
exp(coef) exp(-coef) lower .95 upper .95 Pr(>|z|)
exoKRAS >5% 2.2808 0.4384 1.1827 4.398   0.0139 *
ctDNA Detection 1.3236 0.7555 0.7568 2.315 0.3257
Gender (Male v Female) 1.3433 0.7444 0.7396 2.44 0.3324
ECOG (0 v 1) 1.2631 0.7917 0.5785 2.758 0.5577
ECOG (0 v 2) 2.8138 0.3554 0.9723 8.143   0.0564 .
ECOG (0 v 3) 1.1913 0.8394 0.2942 4.825 0.8062
Metastatic site: Liver v Lung 0.5615 1.7809 0.2193 1.438 0.2289
Metastatic site: Liver v Peritoneal 0.5103 1.9594 0.2083 1.25 0.1413
CA19-9 > 300 1.07 0.9346 0.6041 1.895 0.8166
Regimen: GEM v FOLFIRINOX 0.577298 1.78122 0.9987 3.177 0.0505
Likelihood ratio test= 26.36  on 9 df,   p=0.001782
 beta  HR (95% CI for HR)  wald.test  p.value
exoKRAS >5% 1.5    4.6 (2.2-9.7) 17 0.000041
ctDNA Detection 1    2.8 (1.4-5.7) 8 0.0045
Age 0.017     1 (0.98-1.1) 0.84 0.36
Gender (Male v Female) 0.33    1.4 (0.7-2.8) 0.91 0.34
ECOG (0 v 1) 0.2677 1.307(0.45-3.81) 6.35 0.624
ECOG (0 v 2) 1.2708 3.564(1.04-12.3) 6.35 0.0439
ECOG (0 v 3) 0.8247 2.281(0.41-12.8) 6.35 0.3477
Regimen: GEM v FOLFIRINOX 0.85    2.3 (1.1-5.2) 4.4 0.036
Metastatic site: Liver v Lung -1.2193  0.2954 (0.06948-1.256) 2.76 0.0987
Metastatic site: Liver v Peritoneal -0.2011 0.8178 (0.28198-2.372) 2.76 0.7113
CA19-9 > 300 1.2    3.2 (1.3-7.7) 6.5 0.011
Multi-Analyte Analysis
exoKRAS >5% and CA19-9 > 300 1.7    5.4 (2.6-11) 21 4.90E-06
exoKRAS >5% or CA19-9 > 300 1.2   3.3 (1.3-8.6) 6 0.015
ctDNA Detection and CA19-9 > 300 1.2   3.4 (1.7-6.7) 12 0.00052
ctDNA Detection or CA19-9 > 300 1.8    5.8 (1.4-25) 5.8 0.016
exoKRAS >5% + ctDNA Detection + CA19-9 > 300 1.9 6.6 (3.1-14) 24 9.30E-07
exp(coef) e xp(-coef) lower .95 upper .95
exoKRAS >5% 3.4553 0.2894 1.4044 8.501  0.00695 **
ctDNA Detection 1.6662 0.6002 0.7416 3.744 0.21638
ECOG (0 v 1) 1.2134 0.8242 0.3945 3.732 0.73586
ECOG (0 v 2) 3.1891 0.3136 0.8828 11.52  0.07676 .
ECOG (0 v 3) 1.703 0.5872 0.2692 10.772 0.57162
Metastatic site: Liver v Lung 0.5372 1.8614 0.1102 2.62 0.44215
Metastatic site: Liver v Peritoneal 1.4894 0.6714 0.4822 4.6 0.48868
CA19-9 > 300 2.1451 0.4662 0.8415 5.468 0.10994
Regimen: GEM v FOLFIRINOX 0.612157 1.844406 0.7615 4.468 0.175
Likelihood ratio test= 29.01  on 8 df,   p=0.0003163
Wald test            = 25.22  on 8 df,   p=0.001426
Score (logrank) test = 29.31  on 9 df,   p=0.0005753
Score (logrank) test = 30.93  on 8 df,   p=0.0001446
Univariate Cox Regression (PFS)
Univariate Cox Regression (OS)
Multivariate Cox Regresssion Analysis (PFS)
Multivariate Cox Regresssion Analysis (OS)
Wald test            = 26.03  on 9 df,   p=0.00202
Table 7 Univariate and multivariate analysis of clinical characteristics with exoKRAS and cfKRAS 
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For OS, KRAS MAF  ≥5% in exoDNA (HR 4.6, 95% CI 2.2-9.7, p<0.0001), any ctDNA detection 
(HR 2.8, 95% CI 1.4-5.7, p=0.0045), CA19-9  ≥300 (HR 3.2, 95% CI 1.3-7.7, p=0.011), and an 
ECOG performance status score of 2 (HR 3.56, 95% CI 1.04-12.3, p=0.044) were significant 
predictors of poorer outcomes on univariate analysis.  On multivariate analysis, exoKRAS  ≥5% 
(HR 3.46, 95% CI 1.40-8.50, P=0.007) remained as a significant predictor of poorer OS. An 
exoKRAS MAF ≥5% together with a CA19-9 ≥300 (HR 6.41, 95% CI 2.31-17.80, P=0.0004) at 
baseline treatment naïve status resulted as a significant predictor of poorer OS. Although on its 
own, ctDNA did not emerge as a significant predictor on multivariate analysis, detection of ctDNA 
emerged as a significant predictor of poorer OS when occurring with a CA19-9 ≥300 at baseline 
treatment naïve status (HR 6.37, 95% CI 2.36-17.24, P=0.0003). Additionally exoKRAS MAF 
≥5% and ctDNA detection was correlated to poorer OS  (HR 7.73, 95% CI 2.61-22.91, 
P=0.00002) on multivariate analysis when both occurring at baseline treatment naïve status in 
the same patient, underlining the potential complementary nature of these biomarkers).  
 
Longitudinal monitoring of metastatic PDAC using serial liquid biopsies anticipates on-
treatment progression  
To fully evaluate the utility of liquid biopsies in monitoring the natural history of metastatic PDAC, 
we profiled exoDNA and ctDNA through 123 serial blood draws among 34 patients with a median 
follow-up time of 202 days. Specifically, we selected patients who had at least 2 blood draws 
taken during a concurrent therapeutic regimen, with two or more restaging imagings taken at 
standard 2-3 month intervals.  Among the monitored patients, 20/34 (59%) progressed on 
therapy, with a median time to progression of 176 days.  Patients who did not progress had a 
median follow-up time of 300 days.  Analysis of plasma samples revealed that a KRAS MAF 
peak of ≥1% in any on-treatment serial exoDNA sample was significantly associated with 
eventual disease progression, as determined by RECIST 1.1 (p < 0.0001) (Figure 15).  The 
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optimal MAF of ctDNA KRAS and exoDNA KRAS in predicting progression was assessed by 
ROC analysis with only exoKRAS achieving predictive significance with a sensitivity and 
specificity of 79% and 100%, respectively.  Among the 20 patients who progressed, 16 (80%) 
saw an exoDNA KRAS MAF peak of  ≥1% compared to none in those patients without 
progression 14/14 (100%).  In contrast, serial ctDNA MAF did not correlate significantly with 
presence or absence of progression.  Using a threshold of 20% or greater increase of CA19-9 
during therapy, the sensitivity and specificity of CA19-9 in predicting progression was 70% and 
89%, respectively.  Importantly, when assessing for the length of time when KRAS MAF in serial 
exoDNA exceeded  ≥1% and the subsequent onset of radiological progression, exoKRAS had a 
significantly longer lead time (median of 50 days, p=0.03) compared to lead times obtained by 
using 20% or greater increase in serial CA19-9 (which essentially coincided with the onset of 
radiological progression) (Figure 15C). Additional application of Bayesian inference provided us 
with posterior probabilities of 100% chance of progression given an exoKRAS peak ≥1% 
(P(Progression | exoKRAS ≥1%)) and 90% chance of prolonged response to therapy (No 
progression recorded before censor) given that exoKRAS remains <1% (P(No Progression | 
exoKRAS <1%)). 
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  Figure 15 Tumor monitoring of metastatic PDAC using liquid biopsies 
(A) Tumor monitoring using serial liquid biopsies demonstrating correlation between a exoKRAS 
peak  ≥1% (red line) and radiological progression based on RECIST 1.1 (black line). The standard 
pancreatic cancer biomarker is plotted (blue) as well as ctKRAS (green) for comparison. (B) 
Tumor monitoring among 34 patients demonstrates the ability of exoKRAS peaks ≥1% (red circle) 
to predict radiological progression (green bar). Peaks are identified in 11/14 patients that 
progressed compared to in no patients that did not progress, 9/9. exoKRAS peak is significantly 
associated to progression (p =0.0003) on Fisher’s exact test with an Odds ratio of 62.4 (95% CI 
2.852 - 1367). (C) MAF KRAS peak demonstrates a significantly greater median lead time in 
predicting progression of 50 days (p=0.03) from the time clinically detectable progression was 
evident on CT imaging compared to CA19-9 (median lead time = 0 days).  
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Discussion 
Nucleic acids derived from exosomes have been reported as a novel compartment of high quality 
DNA material which is protected from degradation in circulation (70-72).  As opposed to ctDNA, 
which exists in the 150-170bp range, protected exoDNA is found in a high molecular weight 
format that readily lends itself to next generation sequencing (NGS) for molecular profiling.  In 
our study, we profile matched exoDNA and ctDNA for mutant KRAS alleles by quantitative 
ddPCR in a large series of prospectively collected plasma samples from PDAC patients (N=194), 
and identify baseline detection rates of 61% and 53% in metastatic disease, and 38% and 34% 
in localized disease, for exoDNA and ctDNA, respectively. A substantial minority of patients 
(between 12-25%) with pre-neoplastic pancreatic cysts or non-neoplastic pancreatic diseases 
(such as chronic pancreatitis) harbored detectable circulating mutant.  KRAS mutations are 
present in up to 80% of pre-neoplastic pancreatic cysts (including low-grade mucinous cysts) 
(155, 156), and thus their detection on ddPCR in the circulation is not surprising.  Mutations in 
KRAS are also detectable in the pancreas as a consequence of non-neoplastic inflammatory 
processes such as chronic pancreatitis, although tissue based studies have confirmed a lower 
frequency of mutations than in either cancer or in pre-neoplastic cysts (131, 157, 158).  In line 
with these observations, and as an indirect derivation of “tissue mutation load”, quantitative 
ddPCR found average KRAS MAF to be highest in baseline metastatic samples, followed by 
localized disease, cystic lesions and finally, non-neoplastic panceatic diseases, in that order.   
 
Beyond detection of tumor-derived DNA per se in liquid biopsies as a biomarker of an underlying 
neoplasm, recent studies have also focused on the potential prognostic value imparted by ctDNA 
or exoDNA measurement in cancer patients at the time of presentation.  For example, Mohrmann 
et al reported that among 41 patients with advanced solid cancers, driver mutation detection by 
ddPCR in either exoDNA or ctDNA was associated with overall survival on Kaplan-Meier 
analysis, although only exoDNA at the time of presentation was an independent prognostic factor 
for OS on multivariate analysis (HR 0.15, 0.03-0.80, p= 0.026) (159).  On these lines, several 
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studies have evaluated the prognostic potential of liquid biopsies in PDAC, most focusing on 
ctDNA measured using digital PCR.  In a relatively small study, Earl et al, report  KRAS mutant 
ctDNA detection in 8/31 (26%) patients across various PDAC stages, with detection being 
significantly correlated to OS (HR12.2, p =0.0002) (160).  In a larger study of 105 patients, 
Hadano et  al. report a cumulative rate of 31% ctDNA detection across stages, with median 
survival of 13.6 months vs 27.6 months in those patients with detectable versus no detectable 
ctDNA, respectively, and a significant association with OS (p<0.0001) (161).  In our own series, 
detection of ctDNA and exoDNA at presentation were both associated with significant deleterious 
impact on OS and PFS on univariate analysis, although only an exoDNA KRAS MAF ≥ 5% was 
an independent negative predictor of poor survival on multivariate analysis (HR 2.28, 95% CI 
1.18-4.40, p=0.014 for PFS and HR 3.46, 95% CI 1.40-8.50, p=0.007 for OS, respectively) when 
used independently. As previous work had demonstrated the utility of using a combination of 
biomarkers for early detection, particularly ctDNA and CA19-9 in the context of surgically 
resectable pancreatic cancer, we aimed to determine the prognostic significance of combining 
ctDNA detection or exoDNA MAF with CA19-9 (162, 163). Although ctDNA detection alone was 
not a significant predictor of outcomes, we did observe a combination of ctDNA detection and a 
CA19-9 ≥300 at baseline treatment naïve status to be a significant predictor of poorer OS (HR 
6.37, 95% CI 2.36-17.24, P=0.0003), demonstrating the utility of a multi-analyte approach. We 
also saw this same phenomenon when combining ctDNA detection and exoKRAS MAF ≥5% as 
a significant predictor of OS  (HR 7.73, 95% CI 2.61-22.91, P=0.00002). Ultimately, these blood 
based biomarkers demonstrate complementary utility in prognostic value where the presence of 
these thresholds suggests that those patients may require more intense followup to capture 
earlier progression, or more aggressive therapy than standard of care to influence outcomes. 
This helps underline how each may represent distinct biologies, despite sharing the moniker of 
“liquid biopsy”, whereby ctDNA is released from apoptotic or necrotic cells, while exosomes may 
represent material released into circulation from rapidly dividing viable cells.  
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One major advantage of liquid biopsies is the ability to conduct longitudinal monitoring of on-
treatment patients as a readout of therapeutic efficacy.  While this is typically conducted in PDAC 
with serial imaging scans or with CA19-9, liquid biopsies might provide adjunctive, and potentially 
superior, predictive data on treatment response, with an opportunity for anticipating treatment 
intervention.  In an earlier study, Tjensvoll et al reported pilot data from a cohort of 14 PDAC 
patients, using Peptide–nucleic acid–clamp PCR KRAS mutation detection (164).  Monitoring 
ctDNA levels during chemotherapy demonstrated a correlation with CA19-9 and radiological 
progression among 3 patients.  In a separate series, Sausen et al., used digital PCR for ctDNA 
detection following tumor resection in localized PDAC (36).  Among nine patients with detectable 
ctDNA and radiological recurrence, the authors report ctDNA detection an average of 3.1 months 
after resection compared to 9.6 months when it becomes clinically detectable on CT imaging.  
These data suggest a potential role for using liquid biopsies to facilitate earlier detection of 
progression than radiological scans.  In our cohort, we examined 34 metastatic patients who had 
sufficient longitudinal on-treatment follow-up and serial liquid biopsies to report tumor monitoring 
outcomes.  Although we did not find significant association between progression outcomes with 
changes in ctDNA, we did find a significant correlation between exoDNA KRAS MAF and 
eventual radiological progression.  Specifically, those patients with an exoDNA KRAS MAF  ≥1% 
on any on-treatment serial biopsy have a 100% probability of progressing, with a median lead 
time to radiological progression of 50 days from the first sample with exoDNA KRAS MAF  ≥ 1%.  
In contrast, patients who maintained exoDNA KRAS MAF <1% on serial monitoring had a 90% 
probability of not progressing on therapy in the ~1 year median follow up duration of our study.  
We believe this mutant exoDNA “spike” ≥1%, albeit transient, represents a growth spurt of the 
underlying cancer, likely coinciding with the incipient onset of resistance to ongoing therapy.  The 
ability of serial liquid biopsies to predict which PDAC patients are most likely to fail first or second 
line chemotherapy is of clinical utility, since it provides an earlier opportunity than radiological 
imaging for changing course.  It is also important to note, that continued exposure of patients to 
ineffective first or second line regimens may result in unnecessary toxicities and deterioration of 
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performance status, which might make patients no longer candidates for subsequent line 
therapies.   
 
In addition to metastatic patients, our prospective series also examined the utility of serial liquid 
biopsies in patients with localized PDAC.  At MD Anderson, and increasingly at other centers in 
the US, patients with localized disease receive preoperative (neoadjuvant) chemo-radiation 
therapy.  The main objective of neoadjuvant therapy is to prolong the survival of patients 
undergoing surgery and minimize the use of surgery for patients unlikely to benefit from it (165).  
However, indicators of the effectiveness of neoadjuvant therapy and subsequent surgical 
resection remain a significant unment need.  We postulated that liquid biopsy kinetics between 
initiation and culmination of neoadjuvant treatment may predict for response to neoadjuvant 
therapy and lack of progression, thus enabling surgery.  In fact, a decrease in exoDNA KRAS 
MAF (but not ctDNA) between the beginning and the end of neoadjuvant therapy was significantly 
correlated with eventual surgical resection, when compared to those patients experiencing a rise 
in exoDNA KRAS MAF (OR 38.4, CI 3.95-373.3, p=0.0002).  Although this same correlation held 
true for CA19-9 (OR 28.0, CI 2.65-295.9, p=0.003) which is not significantly different from 
exoDNA, it’s worth noting how liquid biopsies may be used as complementary biomarkers in 
those patients that are deemed CA19-9 non-expressors or those patients with obstructive 
jaundice, where CA19-9 shows no correlation to progressive disease, as in 33% of patients in 
our series.  Notably, even in one case where CT imaging did not detect overt progression despite 
a rise in exoDNA KRAS MAF, laparotomy confirmed the discovery of CT-occult omental 
metastasis.  This data suggests a role for serial liquid biopsies, and specifically exoDNA, as a 
putative predictive biomarker for disease status following neoadjuvant therapy.  
It is important to note several weaknesses of the current study.  Although the strategy of using 
mutant KRAS molecules as a tumor marker may be theoretically optimal in a disease like PDAC 
where KRAS mutation rates exceed 90%, the stochastic nature of circulating nucleic acids 
released in circulation may underestimate the true circulating tumor burden if detection is limited 
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to a single mutation. This may likely be a contributing factor to the poor predictive potential of 
ctDNA in the context of metastatic disease as well as those patients undergoing neoadjuvant 
therapy. Of note, we do find notable differences in our previously published exoKRAS and ctDNA 
detection rates in metastatic (85% and 57.9%, respectively) and localized disease patients (67% 
and 45.5%, respectively) obtained from a retrospective bio-banked cohort (11). The differences 
in detection rate are largely due to the fact that exoDNA and ctDNA in the previous study 
underwent whole genome amplification to increase sensitivity of KRAS detection in the context 
of early detection efforts. Although this was a possibility in the current series, we opted against 
amplification as this would have distorted the MAFs found through ddPCR and thus effected our 
clinical endpoints. It is important to note that the use of a tumor gene panel (e.g. KRAS, TP53, 
CDKN2A, and SMAD4) may achieve greater sensitivity for detection and monitoring (146, 150). 
Additionally, the fact that our multigene panel does not cover KRAS hotspot mutations in codon 
61, may underestimate our true sensitivity as the current panel has theoretical detection rate of 
up to 80% of known KRAS mutations in PDAC. Although our detection rates of KRAS mutant 
molecules are relatively modest at 32% to 41% in baseline treatment naïve metastatic patients 
based on the liquid biopsy compartment, a fact that may limit the amount of patients that may 
benefit from such an assay, when looking at general detection in both compartments at once, 
detection rates increase to 73.1%, which is near the theoretical limit of our assay. This underlines 
the complementary nature of these biomarkers, especially in setting of low volume disease (such 
as post-treatment, or monitoring fore recurrence), whereby the absence of mutant detection in 
one does not preclude the ability to gain valuable genomic information in the other. Additionally, 
although exoDNA mutant KRAS detection levels compared to ctDNA detection levels are not 
significantly better in the current cohort, exosomes provide the added ability to perform specific 
enrichment of cancer-derived material, allowing for capture of DNA, RNA, and proteins derived 
from tumors for mutation, gene expression, and possibly even neoantigen detection (14). The 
need of a gold standard validation is also important when pursuing liquid biopsy assays such as 
the one described in this study. As such, recent work has attempted to validate concordance 
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between mutations found in liquid biopsies and tissue biopsies (166-171). In the context of 
PDAC, acquiring tissue biopsies for molecular profiling is particularly difficult in the metastatic 
setting where fine needle aspirates are typically reserved for diagnostic purposes. We thus 
selected a small cohort of 34 localized disease patients where concordance rates ranged from 
66.7% to 95.5% depending on the liquid biopsy and tissue source. Unsurprisingly, surgical tissue 
specimens saw greater rates  of concordance, particularly in exoDNA which is likely associated 
to the greater sensitivity of mutation detection within exosomes. Overall, KRAS mutation 
detection rates was high within liquid biopsies as a whole, although it remains to be seen if 
profiling of additional mutations can achieve this sensitivity and specificity.  
 
In conclusion, our study in a relatively large cohort of PDAC patients, comprised of both 
metastatic and localized disease, reiterates the predictive and prognostic value of liquid biopsies 
in this malignancy.  We demonstrate that while the baseline CA19-9, exoDNA, and ctDNA cargo 
has prognostic effect, longitudinal monitoring of exoDNA provides unique predictive information 
on the outcome of neoadjuvant therapy in localized disease, and in anticipating progression in 
the metastatic setting.  In contrast to the challenges of repetitive tissue biopsies for visceral 
cancers, serial liquid biopsies may provide an attractive alternative strategy to map tumor 
evolution in real time, providing an unprecedented insight into how the PDAC genome adapts to, 
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Abstract 
Background:  The ability to perform comprehensive profiling of cancers at high-resolution is 
essential for precision medicine. Liquid biopsies using shed exosomes provide high-quality 
nucleic acids to obtain molecular characterization, which may be especially useful for visceral 
cancers that are not amenable to routine biopsies. 
  
Patients and Methods: We isolated shed exosomes in biofluids from three patients with 
pancreaticobiliary cancers (two pancreatic, one ampullary).  We performed comprehensive 
profiling of exoDNA and exoRNA by whole genome, exome and transcriptome sequencing 
using the Illumina HiSeq 2500 sequencer.  We assessed the feasibility of calling copy number 
events, detecting mutational signatures and identifying potentially actionable mutations in 
exoDNA sequencing data, as well as expressed point mutations and gene fusions in exoRNA 
sequencing data. 
  
Results: Whole exome sequencing resulted in 95 to 99% of the target regions covered at a 
mean depth of 133 to 490x.  Genome-wide copy number profiles, and high estimates of tumor 
fractions (ranging from 56 to 82%), suggest robust representation of the tumor DNA within the 
shed exosomal compartment.  Multiple actionable mutations, including alterations in NOTCH1 
and BRCA2, were found in patient exoDNA samples.  Further, RNA sequencing of shed 
exosomes identified the presence of expressed fusion genes, representing an avenue for 
elucidation of tumor neoantigens.   
  
Conclusions: We have demonstrated high-resolution profiling of the genomic and 
transcriptomic landscapes of visceral cancers.  A wide range of cancer-derived biomarkers 
could be detected within the nucleic acid cargo of shed exosomes, including copy number 
profiles, point mutations, insertions, deletions, gene fusions and mutational signatures.  Liquid 
biopsies using shed exosomes has the potential to be used as a clinical tool for cancer 
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diagnosis, therapeutic stratification, and treatment monitoring, precluding the need for direct 
tumor sampling.  
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Patients and samples 
Three patients with pancreatobiliary cancers were included in our comprehensive liquid biopsy 
study (supplementary Table S1), and each was consented following institutional review board 
approval (PA15-014).  Case LBx01 is a 57-year old man who initially presented with stage IIA 
PDAC.  He received neoadjuvant gemcitabine-based chemoradiation therapy with subsequent 
R0 resection and adjuvant gemcitabine.  He was diagnosed with multifocal pulmonary 
recurrence on surveillance imaging 16 months after completion of adjuvant therapy, and 
confirmed pathologically by thoracoscopic wedge resection of one dominant lesion.  Whole 
exome and RNA sequencing were performed on the metastatic lung tissue (by Dr. Arul 
Chinnaiyan at the University of Michigan). Thirteen months subsequent to surgical 
metastatectomy, the patient then developed evidence of pleural effusion, and therapeutic 
thoracentesis yielded 800 mL of pleural fluid from which shed exosomes were isolated and 
downstream whole genome, exome and RNA sequencing analyses were performed.  Case 
LBx02 is a 68-year old woman with PDAC primary and hepatic metastases.  Thirty mL of whole 
blood were collected via standard blood draw prior to initiation of chemotherapy and exosomes 
were isolated for subsequent tumor profiling analyses.  Case LBx03 is a 74-year old man who 
underwent an upfront pancreaticoduodenectomy for an ampullary mass.  Final pathology 
confirmed a stage IIB pancreatobiliary type adenocarcinoma of the ampulla. He received 
platinum-based adjuvant chemoradiotherapy and had no evidence of recurrence 5 months after 
completion of definitive therapy. Thirty mL of peripheral whole blood were collected upon the 
patient’s referral to MD Anderson Cancer Center after resection, but prior to beginning any 






  91 
Introduction 
  
For many visceral cancers, such as pancreatic ductal adenocarcinoma (PDAC), the availability 
of tissue-based companion diagnostics may be limited or precluded secondary to clinical 
factors such as tumor location, amount of tumor tissue sampled or procedure-associated risk, 
hindering the progress of precision medicine (172).  Relatively non-invasive liquid biopsies offer 
a promising alternative for tumor characterization and disease monitoring.  To this end, several 
investigators have identified tumor-specific genetic mutations in patient plasma-derived 
circulating cell-free DNA (cfDNA) including activating mutations in KRAS, BRAF, EGFR and 
other cancer genes using highly-sensitive targeted approaches such as digital PCR and 
targeted amplicon sequencing on cfDNA (173-175). Recently, whole genome and exome 
sequencing have been performed using the cfDNA of plasma samples in an effort to estimate 
tumor copy number profiles and identify actionable mutations in a more agnostic manner (45, 
176, 177).  However, the extensively fragmented nature of cfDNA in circulation makes it difficult 
for this format to become generalizable in the context of genomic characterization of tumors 
through current next-generation sequencing (NGS) platforms (85). This limitation is even more 
profound in the context of circulating RNAs, where profiling is essentially restricted to small 
microRNAs, due to extensive fragmentation of coding transcripts (86, 87, 178). 
 
Exosomes are 40-150 nanometer-sized membrane-bound extracellular vesicles that arise by 
specific endosomal biogenesis pathways (179).  Functionally, exosomes have been shown to 
influence the tumor microenvironment as vehicles for cell-cell communication in cancer, 
harboring a diverse repertoire of molecular cargo that are shielded from degradation in 
circulation and that are representative of their originating cells (67, 179, 180).  Therefore, the 
quality, diversity and tumor-specific nature of exosomal DNA (exoDNA), and exoRNA provide a 
potentially favorable alternative compared to cell-free nucleic acids for comprehensive tumor 
profiling at high-resolution.  Indeed, recent publications have shown that exosomes contain 
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genomic representations of high molecular weight (HMW; >10kb), double-stranded fragments 
of DNA (70, 71). 
We sought to assess the feasibility and potential clinical utility of characterizing the entire 
genomic and transcriptomic profiles of visceral cancers using the nucleic acid cargo within shed 
exosomes obtained from a single specimen of patient biofluid.  We show, for the first time, that 
it is possible to perform integrative profiling of tumors from shed exosomes by analyzing the 
DNA and RNA cargo using standard NGS platforms, and that this approach has the potential to 
circumvent the need for direct tumor sampling in visceral cancers. 
  
  93 
Results 
Plasma and pleural effusion exosome isolations are enriched with high molecular weight 
double-stranded genomic DNA 
Shed exosome populations were confirmed by scanning electron microscopy and transmission 
electron microscopy (Figures 16A and B).  Nanoparticle-tracking analysis (Particle Metrix Inc.) 
confirmed the presence of exosome-sized vesicles in the liquid biopsy of all three patients 
(Figure 16C).  Expression of canonical exosome surface markers, including the tetraspanin 
CD63 by flow cytometry and CD9, CD63, CD81 and HSP70 by western blots (Figure 16D and 
E) also established the presence of exosomes in our isolations. Extraction of exoDNA revealed 
quantifiable HMW double-stranded DNA (dsDNA; >10kb in size) as seen in Figure 16F. 
 
Exosomes contain a large fraction of tumor DNA 
KRAS mutant allele frequency (MAF) was determined using the KRAS multiplex screening 
assay and droplet digital PCR platform (ddPCR, BioRad Technologies, see Supplementary 
Methods) demonstrating tumor presence in our exosome isolations (Figure 16G).  PCR-based 
analysis of mutant KRAS and BRCA2 pre- and post-whole genome amplification demonstrated 
conserved MAFs (Figure 17).  In addition, genome wide copy number profiling identified 
somatic copy number changes across the genomes of each patient.  High estimates of tumor 
fractions ranging from 56 to 82% for each liquid biopsy sample suggests stout representation of 
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 Figure 16 Characterization of exosomes isolated from liquid biopsies  
A: Scanning electron microscopy of exosomes from plasma PDAC sample. 
B: Illustrates that vesicle diameters are frequently only 5- to 10-fold greater than the 
bilayer thickness, which is typical of the internal vesicles of multivesicular bodies. 
C: Size and counts of particles per ml biofluid (plasma or pleural effusion) as measured 
by nanoparticle tracking analysis.  The size distribution is in the range of exosomes (40-
150 nm) and other microvesicles. 
D: Enriched exosomes were captured using the CD63+ Dynabeads. Dynabead bound 
exosomes were stained with PE Mouse Anti-Human CD63. Isotype control was stained 
by Simultest IgG2a/IgG1. The gating strategy for single beads is shown (left) with 
effective capture of CD63+ exosomes as demonstrated by the shift in fluorescence 
(right). 
E: Western blots for exosomal markers (CD81, CD63, CD9 and HSP70) show that bands 
at the expected size were observed for multiple markers. Pa04C protein whole cell lysate 
is used as a protein expression control and human serum-derived exosomes (+ cont.) is 
use for the exosomal marker control. 
F: Example of an exoDNA obtained from a clinical PDAC patient. Image shows the 
performance in the electropherogram of a HMW exoDNA pre and post WGA. Exosomes 
contain HMW DNA (>10kb in size), as determined using an Agilent tape Station 2200. 
AUC also show HMW DNA concentration higher than 60ng per microliter from a 20 
microliter total volume, enough DNA for NGS on clinical samples. 
G: ExoDNA was isolated from plasma of an advance case of PDAC.  The sample on top 
comes from an individual with advanced PDAC (LBX03). Using ddPCR on 1μL of 
exoDNA eluate, we are able to detect mutant KRAS, blue dots (mutant droplets), green 
dots represent wild type sequences. Allele frequency of KRAS genes is preserved pre- 
(42%) and post-whole genome amplification (37%) (lower panel). 
 
 










Figure 17 Sanger sequencing validation of exoDNA mutation 
BRCA2 Sanger sequencing validation in the pre- and post-amplified exoDNA shows 
preservation of allele frequencies approximately 80-90% pre and post-amplification. 
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ExoDNA is representative of the entire human genome 
Whole genome sequencing covered 65 to 91% of the human genome at a mean depth of 12 to 
35x at high sequencing quality with 88.2 to 92.5% of bases having greater than or equal to 
sequencing quality scores of Q30.  Exome sequencing covered 95 to 99% of the targeted 
genome (54 megabases) with at least one read at a mean depth of 133 to 490x with 73 to 96% 
being covered by at least 10 reads.  Ninety to 94.6% of bases represented high quality sequence 
suggesting that exoDNA in our samples is representative of the entire human genome. 
 
Comprehensive profiling of tumors using exoDNA and mRNA 
LBx01: Tumor profiling using pleural effusion exosomes from a patient with pancreatic 
ductal adenocarcinoma with previously resected lung metastasis 
LBx01 is a patient PDAC, who underwent a thoracoscopic resection of a suspicious pulmonary 
nodule, subsequently confirmed to be metastasis.  Fifteen months later, he developed a pleural 
effusion, which contained less than 1% malignant cells on cytospin, per final cytopathology 
report.  A deep NGS assay performed on the pleural fluid cytospin failed to detect any evidence 
of tumor DNA.  In contrast, abundant cancer-derived exosomes were present in the pleural fluid 
even with the marked paucity of cancer cells.  The pleural effusion exoDNA had a computationally 
estimated tumor fraction of 82% (95% confidence region (CR) of 81-83%) and a mean genome 
copy number of 2.57.  The exoDNA tumor fraction estimate was higher than that compared to 
the previously resected metastatic lung tissue (23%, 95% CR, 22-24%).  The exoDNA mutation 
rate was estimated at 341 mutations/Mb compared to 2.06 mutations/Mb in the metastatic lung 
tissue DNA 15 months prior to the liquid biopsy sampling.  This substantially higher mutational 
load is not surprising given the time between metastectomy and manifestation of pleural effusion, 
and the multi-drug cytotoxic chemotherapy regimen administered to the patient.   
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Potentially actionable mutations are listed in Table 8.  We considered mutations to be potentially 
actionable if they are either putative drivers (recurrently mutated in COSMIC (100)) that could be 
monitored over the course of patient management, or COSMIC mutations that reside in genes 
associated with a clinical trial or cancer drug (see Supplemental Methods).  Mutations in KRAS 
and TP53 were identified in both the lung metastatic tissue and the subsequent pleural effusion.  
Mutations likely representative of progression include those in APC and CHEK2.  The metastatic 
lung tissue harbored a mutation signature with peaks at C-to-T base substitutions that are 
consistent with Signature 1 of the COSMIC mutational signatures (Figure 18C), a common 
cancer signature proposed to be involved in spontaneous deamination of 5-methylcytosine (100, 
113).  The exoDNA mutational signature deviates from this, which suggests that additional 
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ExoDNA copy number profiling showed that 27% of the genome exhibited copy number variation 
(Figure 18A).  This included amplification of MYC (copy number (CN)=3; P-val=1.3e-72), KRAS 
(CN=6; P=2.7e-11), EGFR (CN=3; P=1.3e-138) and ERBB2 (CN=5; P=6.1e-10).  ERBB2 
amplification, in particular, was also identified in the previously resected lung metastasis, albeit 
at a lower copy number.  We confirmed the amplification and overexpression, respectively, 
ERBB2 in both exoDNA and exoRNA, where the estimated copy number was 5 and ERBB2 was 
over-expressed at 85.13 transcripts per million (TPM) which represents a 3.62 times higher 
expression compared to normal pancreas tissue (23.52 TPM - the median ERBB2 expression in 
normal pancreas tissue identified from the Genotype-Tissue Expression (GTEx) project (181)).   
A key advantage of exoRNA (in contrast to cell free nucleic acids) is the preserved quality of 
transcripts that allows for assessment of an aberrant transcriptome in the same liquid biosample 
from which the genomic landscape is derived.  As exemplified with ERBB2, cross comparison of 
exoDNA and exoRNA data permits precise delineation of the oncogenic targets of genomic copy 
number aberrations.  Another potential clinical benefit of this approach is identification of 
expressed neoantigens from the tumor, be it missense mutations, or unique cancer-derived 
fusion transcripts, which can serve as the basis for identification of neoantigen-targeted humoral 
or cellular immune responses (182, 183).  For example, the exoRNA confirmed presence of a 
KRAS G12D mutation in the transcriptome (Figure 18B).  Furthermore, 87.8% of protein-coding 
transcripts were expressed (having greater than or equal to 2 TPM) and 40 putative expressed 
gene fusions were identified (Figure 18D), though no delineated cancer signaling pathways were 








Figure 18 LBx01 tumor profiling 
(A) Copy number profile comparison between the metastatic lung tissue (top) sampled 15 months 
before the pleural effusion exoDNA (bottom). The cancer-related genes on the light-red vertical 
bars have copy number gains and those on the light-blue vertical bars have copy number losses, 
where the numbered labels represent the estimated copy numbers. The yellow vertical bar 
annotates putatively actionable copy number variations (CNVs) (e.g. ERBB2). The arrow to the left 
depicts the progression of cancer-associated CNVs between the 2 time points. These happen to 
all be amplifications, which were also confirmed to be upregulated in the exoRNA compared with 
that in the metastatic lung tissue RNA-seq.  
 


















LBx02: Tumor profiling using blood-derived exosomes of a pancreatic ductal 
adenocarcinoma patient 
 (B) Mutant KRAS was identified in the mRNA (RNA sequencing) as well as DNA (exome and 
genome sequencing) of the pleural effusion exosomes. (C) Mutational signature of the plasma 
exosomes derived from exome sequencing (top) and genome sequencing (middle) compared with 
the mutational signature of the metastatic lung tissue (bottom). (D) Circos plot illustrating putative 
gene fusions (blue), lung metastatic copy number profile (inner-most ring), pleural effusion 
exosomes copy number profile (second inner-most ring) and gene aberrations. Mutations seen in 
the pleural effusion are black and those seen in both the metastatic lung tissue and pleural effusion 
are in bolded black. 
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LBx02 is a treatment-naïve patient with PDAC and hepatic metastases. The plasma exoDNA 
estimated tumor fraction was 56% (95% CR of 54-57%) with a mean genome copy number of 
2.12.  Copy number profiling showed that 9% of the genome exhibited copy number variation 
(Figure 19A).  This included amplification of MYC (CN=13; P=4.7e-08), KRAS (CN=3; P=6.5e-
24) and loss of TP53 (CN=1; P=3.6e-39).  Potential actionable mutations (Table 9) include 
mutations in ERBB2, KRAS, NRAS and NOTCH1 (in practice, KRAS or NRAS mutations are not 
strictly actionable, although many commercially available or academic center-initiated 
sequencing panels list them as such).  The exoDNA exhibited a mutation rate of 77 mutations/Mb 
and a profile resembling Signature 1 of the COSMIC mutational signatures (Figure 19B) (100, 
113).   
Approximately 9% of protein-coding transcripts were expressed in the exoRNA and 16 putative 
expressed fusions were identified (Figure 19C).  The mTOR signaling pathway was over-
















Figure 19 LBx02 tumor profiling  
(A) Copy number profile of the plasma exoDNA. (B) Mutational signature of the pleural effusion 
exosomes derived from exome sequencing (top) and genome sequencing (bottom). (C) Circos plot 
illustrating putative gene fusions (blue), plasma exoDNA copy number profile (inner-most ring) and 
potential actionable genes (blue, deletions; red, amplifications; black, somatic point mutations). 
 


























LBx03: Tumor profiling using blood-derived exosomes of an ampullary carcinoma patient 
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LBx03 plasma exoDNA had an estimated tumor fraction of 82% (95% CR of 81-84%) and a mean 
genome copy number of 2.5.  Copy number profiling showed that 53% of the genome exhibited 
copy number variation (Figure 20), which suggests the presence of an “unstable” genome 
phenotype (40).  Copy number aberrations include amplification of MYC (CN=4; P=6.7e-129) 
and KRAS (CN=3; P=3.8e-69).  The exoDNA mutation rate is estimated at 125 mutation/Mb 
exhibiting a relatively large proportion of C-to-A and C-to-T base substitutions  (Figure 20B).  
Several potentially actionable mutations were identified (Table 10) including an unexpected 
somatic mutation of BRCA2, which was not present in the germline DNA.  Specifically, the 
BRCA2 V3091I mutation has previously been reported as conferring a homologous 
recombination defect in cancer cells (184).  Three lines of evidence suggest that this BRCA2 
mutation is indeed pathogenic: first, the high MAF in exoDNA, underscoring its “driver” status, 
second the “unstable” genome phenotype on genome-wide copy number assessment (40), and 
third, the exceptional response to a platinum-containing adjuvant regimen that this patient has 
had to date (although the overall follow-up period remains limited).   
 
In the exoRNA, 16.6% of protein-coding transcripts were expressed, including 40 putative 
expressed gene fusions (Figure 20C).  No cancer signaling pathways were overrepresented in 
the exoRNA data.  
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Figure 20 LBx03 tumor profiling 
(A) Copy number profile of the plasma exoDNA. (B) Mutational signature of the plasma 
exosomes derived from exome sequencing (top) and genome sequencing (bottom). (C) 
Circos plot illustrating putative gene fusions (blue), plasma exoDNA copy number profile 
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Discussion 
 
We have demonstrated the feasibility of using peripheral blood and pleural effusion based liquid 
biopsies to comprehensively profile the genomes and transcriptomes of deeply located visceral 
cancers for which traditional tissue biopsies may be difficult, risky, or unachievable in less-
specialized centers. In addition, exosome-based liquid biopsy results demonstrate the potential 
for identifying unexpected therapeutic vulnerabilities.  Of particular importance regarding patient 
LBx03, is the presence of a BRCA2 mutation, which has been shown to predict responsiveness 
to platinum-based chemotherapies. Currently, several clinical trials are ongoing that incorporate 
platinum-based regimens of PARP inhibitors in PDAC patients with such DNA damage repair 
defects (185).  In addition to identifying actionable mutations at the time of presentation, 
exosome-based liquid biopsies provide an opportunity to identify new therapeutic vulnerabilities 
that emerge over the course of treatment, or elucidate potential mechanisms of resistance to 
administered targeted therapies.  For example, at the time of metastectomy of the lung 
metastasis from LBx01, the patient was found to have evidence of ERBB2 amplification in the 
pulmonary nodule, leading to subsequent attempt of targeted therapy with Trastuzumab.  
However, no meaningful response was found to the agent.  Two months following completion of 
this therapy, subsequent liquid biopsy from this patient confirmed the ERBB2 amplification, as 
well as the emergence of an EGFR amplification, which might represent a clonal selection in 
response to the trial of a targeted agent (186).  Liquid biopsy in this patient far exceeded standard 
of care lab metrics where less than 1% tumor cells were detected in the pleural effusion, 
precluding further analysis.  Cancer-derived exosomes were able to enrich for the genetic make-
up of the local tumor tissue, recapitulating the molecular identity of the diseased lung. It is 
important to note that such “serial” sampling of the tumor genomic landscape, while possible in 
superficial cancers like melanomas, is almost unheard of in visceral malignancies, due to 
logistical or reimbursement limitations. 
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While cfDNA platforms can certainly elucidate limited panels of genomic abnormalities and even 
map the emergence of resistance mechanisms during the course of targeted therapies, 
exosome-based liquid biopsy approaches have the additional benefit of being able to 
comprehensively profile the cancer transcriptome from the same biosample.  In particular, the 
ability to identify expressed neoantigens (point mutations or fusion transcripts) represents an 
avenue to interrogate the humoral or cellular responses to such neoantigens in visceral cancers 
(182, 184).  For example, emerging “personalized” adoptive T cell therapies require elucidation 
of cancer-specific neoantigens that are expressed and processed in an HLA context (187).  
Typically, this requires a tissue biopsy and RNA profiling of the tumor.  Exosome-based liquid 
biopsy can identify such expressed neoantigens without the need for tissue sampling, and 
moreover, map the response to immunotherapy through quantitative estimates of neoantigen 
load in circulation.  In addition, since the peripheral blood is a sampling of all body tissues, this 
genetic analysis presumably has the power to characterize the patient’s entire tumor burden: 
primary tumor and any metastatic disease.  This is of particular importance when considering 
that primary tumors and associated metastases are of a heterogeneous genetic makeup with 
compounded temporal heterogeneity (188). 
 
Our study is not without limitation.  Conceptually, many will desire to see liquid biopsy detected 
mutations validated in primary tissue.  For visceral cancers, the acquisition of such tissues may 
be limited and localized, thus detection of mutations for validation may not be ideal.  Of note, our 
mutation rates of 341, 77 and 125 mutations/Mb are substantially higher than the average of 2.64 
mutations/Mb (range 0.65-28.2) estimated by Waddell et al (40) from PDAC tissue whole genome 
sequencing.  We suspect that a large degree of this discrepancy is due to exoDNA representing 
tumor heterogeneity at a level that is not attainable through tissue sequencing. A potential 
strategy to confirm these liquid biopsy findings is to compare serial samples in the same patient, 
to validate over time the identification of mutations at varying allelic frequency.  Such serial 
profiling is the subject of further study.  Nonetheless, our proof of concept results demonstrate 
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that seamless coordination between clinical and research efforts can produce a workflow from 
blood draw to sequencing results in a period of 14 days, acquiring results in a clinically relevant 






















Chapter 6 - Surfaceome profiling enables isolation of cancer-specific exosomal cargo in 
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Abstract 
Background 
Detection of circulating tumor DNA (ctDNA) can be limited due to their relative scarcity in 
circulation, particularly while patients are actively undergoing therapy. Exosomes provide a 
vehicle through which cancer-specific material can be enriched from the compendium of 
circulating non-neoplastic tissue-derived nucleic acids. We performed a comprehensive 
profiling of the pancreatic ductal adenocarcinoma (PDAC) exosomal “surfaceome” in order to 
identify surface proteins that will render liquid biopsies amenable to cancer-derived exosome 
enrichment for downstream molecular profiling. 
  
Patients and methods 
Surface exosomal proteins were profiled in 13 human PDAC and 2 non-neoplastic cell lines by 
liquid chromatography-mass spectrometry. A total of 173 prospectively collected blood samples 
from 103 PDAC patients underwent exosome isolation.  Droplet digital PCR (ddPCR) was  
used on 74 patients (136 total exosome samples) to determine baseline KRAS mutation call 
rates while patients were on therapy. PDAC-specific exosome capture was then performed on 
additional 29 patients (37 samples) using an antibody cocktail directed against selected 
proteins, followed by ddPCR analysis. Exosomal DNA in a PDAC patient resistant to therapy 
were profiled using a molecular barcoded, targeted sequencing panel to determine the utility of 
enriched nucleic acid material for comprehensive molecular analysis. 
  
Results 
Proteomic analysis of the exosome “surfaceome” revealed multiple PDAC specific biomarker 
candidates: CLDN4, EPCAM, CD151, LGALS3BP, HIST2H2BE and HIST2H2BF. KRAS 
mutations in total exosomes were detected in 44.1% of patients undergoing active therapy 
compared to 73.0% following exosome capture using the selected biomarkers. Enrichment of 
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exosomal cargo was amenable to molecular profiling, elucidating a putative mechanism of 
resistance to PARP inhibitor therapy in a patient harboring a BRCA2 mutation. 
  
Conclusion 
Exosomes provide unique opportunities in the context of liquid biopsies for enrichment of 
tumor-specific material in circulation. We present a comprehensive surfaceome 
characterization of PDAC exosomes which allows for capture and molecular profiling of tumor-
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Introduction 
An emerging body of literature demonstrates that comprehensive characterization of cancer 
genomes has both diagnostic and prognostic utility, and may provide insights into formulating 
individualized treatment strategies (40, 80). However, even with large scale sequencing efforts, 
accessibility of tumor tissue is often limited by both patient- and/or system-centered factors.  
Tissue sampling of pancreatic ductal adenocarcinoma (PDAC) may be limited to an initial 
diagnostic FNA, while risk of biopsy, locally destructive therapies, cost or facility capabilities may 
limit further sampling efforts. “Liquid biopsy” is a less invasive strategy for tumor sampling, which 
may circumvent the need for tissue biopsy while still affording high resolution profiling of the 
genomic landscapes of visceral cancers. Within the field of liquid biopsy, tumor-derived 
extracellular vesicles (EVs) such as exosomes, are a source of high-quality nucleic acids for 
molecular characterization with inherent utility for diagnostic and therapeutic purposes (154). 
  
Exosomes are nanometer-sized membrane-limited extracellular vesicles that arise from 
endosomal biogenesis pathways and serve as critical means of cell-cell communication (189). 
Tumor-derived exosomes contain membrane-tethered proteins, microRNAs, and as recently 
demonstrated, entire genomic complements of DNA (exoDNA)  (70, 71, 190, 191). Exosomes 
are shed from both tumor and non-neoplastic cells into the peripheral circulation.  Therefore, one 
of the potential pitfalls of utilizing exosomes, and essentially any liquid biopsy component 
including circulating tumor DNA (ctDNA), as a surrogate for the tumor genome is that genetic 
information obtained from such exosomes will be diluted in large part with the DNA of non-cancer 
cell-derived exosomes. Exosomal surface biomarkers provide a means to separate cancer from 
non-cancer derived exosomes through the use of bead-based selection of such markers.  While 
exosomes are known to express tetraspanins such as CD63, CD9, and CD81, these biomarkers 
are not specific to cancer-derived exosomes.  Specific markers to distinguish normal and cancer 
tissue derived exosomes is an area of active research, particularly in PDAC where the use of 
such biomarkers have great potential in early disease detection (138, 192). Here, we identify a 
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panel of PDAC-specific exosomal surface proteins, demonstrate the ability to enrich for PDAC-
derived exosomes in circulation using these identified proteins, and then show the feasibility of 
mutation profiling of enriched exoDNA samples through next-generation sequencing (NGS).  
 
Results 
“Surfaceome” profiling of exosomes 
Surface and cargo exosomal proteins were profiled in 13 human PDAC cell lines, and 2 non-
neoplastic cell lines (HPNE and CAF19) through liquid chromatography-mass spectrometry 
(MS). Proteomes from exosome surface and cargo were fractionated at an intact protein level 
and then subjected to trypsin digestion and MS-based analysis. A total of 7086 proteins 
(corresponding to 3663 gene symbols) were identified.  Requiring expression on the surface of 
at least 3 samples (i.e. the proposed exosomal “surfaceome”) demonstrated the presence of 
canonical proteins universally expressed in exosomal populations including CD81, CD9, and 
TSG101 resulting in 1057 proteins (corresponding to 482 genes;). In order to identify a panel of 
PDAC-specific surface exosomal markers, resulting “surfaceome” proteins that were found to be 
expressed in at least 3 PDAC cell lines with a maximum of 1 spectral count being expressed in 
non-neoplastic cell lines were considered candidate PDAC-specific exosomal surface 
markers.  In addition, we annotated these candidates using the extracellular vesicle database 
ExoCarta (database of exosomes proteomics, including data from 160 exosome experiments 
and 166 samples based on mass spectrometry analyses), which contains human exosome 
protein profiles from normal and cancer tissue sources to effectively assess the absence of our 
candidate proteins from vesicles of non-neoplastic origin. Further curation and validation of these 
biomarkers was prioritized based on biological rationale and availability of targeting antibodies 
(Figure 21).  







Figure 21 Cancer-specific exosomal biomarker selection and validation  
(A) Heat map representation of proteins that are expressed on the surface of pancreatic 
ductal adenocarcinoma exosomes that are not expressed (or expressed at very low levels) on 
the surface of HPNE and CAF19 exosomes. (B) Western blot validation of identified candidate 
biomarkers: protein expression analysis of cell lysates (left) compared with exosomes (right) 
of neoplastic (Pa01C, Pa03C, and Pa04C) and non-neoplastic (CAF19 and SC2) cell lines. 
CD63 and TSG101 are used as antibody controls for identification of exosome populations. 
Most selected biomarkers show enriched specificity towards being present in cancer 
exosomes versus normal exosomes. 
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Biomarker validation 
Candidate proteins were validated through western blot analysis of PDAC cell line derived 
exosomes from Pa01C, Pa03C, and Pa04C (Figure 21).  Non-neoplastic cell lines CAF19 and 
SC2 were used as controls. Candidate biomarkers were detected within protein lysates of cell 
lines with varying degrees of sensitivity and specificity, but were effectively enriched within the 
exosome protein fractions. In other words, protein biomarkers such as CD151 and HistoneH2B 
(H2B) are found in the protein lysates from all cell lines, including non-neoplastic cell lines, but 
are only found within exosomes derived from PDAC cell lines. On the other hand, LGALS3BP is 
present in all exosomal populations, but is overexpressed in tumor derived exosomes when 
compared to non-neoplastic sources. In contrast, the recently published PDAC exosomal 
biomarker glypican-1 (GPC1), did not demonstrate significant expression in tumor-derived 
exosomes and in fact appeared to be selectively expressed in non-neoplastic sources when four 
separate GPC1 antibodies were tested, including the originally reported clone (ThermoFisher, 
PA5-28055)  (Figure 22) (138). This profiling analysis led to a final antibody cocktail targeting 
the following candidate biomarkers:  anti-CLDN4, EPCAM, CD151, LGALS3BP, HIST2H2BE and 
HIST2H2BF, respectively used for subsequent enrichment studies. 
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Validation of capture assay in clinical samples 
Following selection of our candidate biomarkers, we designed an immunocapture pulldown assay 
to specifically capture enriched populations of cancer-derived exosomes. Aldehyde/sulfate latex 
beads were coated with the five antibodies of choice as a cocktail targeting the identified and 
validated exosome protein biomarkers. In this fashion, we selectively enriched for cancer derived 
exosomes by pulling down only those extracellular vesicles exhibiting the above biomarkers from 
the overall shed exosome population. By using PE-CD63 (a pan-exosome marker) fluorescence 
Figure 22 Western blot analysis of GPC1 
Western blot analysis of four GPC1 commercially available antibodies which we 
attempted to validate for tumor exosome specific detection. No protein was seen at the 
expected size range to suggest that this biomarker could be cancer exosome specific. 
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signal as a surrogate for overall effective exosome capture, we then measured the sensitivity 
and specificity of the enrichment method. Specifically, by selecting for exosomes using anti-
CD63, we are able to detect the presence of exosome populations in all of our cell line isolates 
(Figure 23), but effectively avoid non-specific binding of exosomes using our blocking buffer as 
shown by the lack of fluorescence (Figure 23C). Finally, when the beads are coated with our 
biomarker antibodies of interest, specific capture of cancer derived exosomes compared to non-
neoplastic derived exosomes is apparent (Figure 23D).   
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Figure 23 Exosome capture assay methodology 
(A) Pulldown assay incubating aldehyde/sulfate latex beads with the cocktail of antibody 
markers of choice. The aldehyde groups grafted onto the surface of these beads enables 
facile coupling of proteins to the surface of the particle. Following coating of the bead with 
the antibody of choice, non-coated surfaces are blocked with a BSA/Glycine buffer to 
prevent nonspecific binding of exosomes. Beads are then incubated with exosomes 
overnight resulting in an enriched population of vesicles based on the marker of choice 
which is amenable to downstream molecular analysis. (B) Pulldown assay is able to 
capture exosomes with minimal unspecific binding to first determine effective capture of 
exosomes using our assay, beads coated with CD63 antibody were incubated with either 
neoplastic (Pa04C) or non-neoplastic (SC2) derived exosomes and subsequently tagged 
with a CD63-PE conjugated secondary antibody (a pan-exosome marker). Results based 
on flow cytometry show effective capture of exosome populations using this assay.  
 
 















(C) To confirm no non-specific binding of exosomes and effective blocking strategy, beads 
were first incubated with blocking buffer (BSA+Glycine), and then underwent subsequent 
incubation with the antibody of choice followed by cell line derived exosomes. The 
resulting beads were then treated with the CD63-PE conjugated secondary antibody and 
profiled using flow cytometry. This demonstrates that no exosomes were detected being 
bound to the beads, confirming no non-specific exosome binding. (D) Specific capture of 
PDAC cell line exosomes using this methodology was then validated in a representative 
candidate pulldown markers (EPCAM), demonstrating that beads specifically capture 
exosomes only when incubated with those coming from PDAC cell lines (Pa04C and 
Pa03C), and not non-neoplastic cell lines (HPNE, SC2, CAF19).  
 
 
  122 
We next aimed to implement our enrichment methodology for PDAC-derived exosomes on 
patient plasma samples to determine its effectiveness at detecting tumor derived DNA during 
therapy (Table 10).  
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50 14     
Clinical Staging 
   
 Resectable  Stage IA 7 2  
 Stage IB 8 6  
 Stage IIA 26 4  
 Stage IIB 11 5 
 Locally Advanced  Stage III 30 8 
 Metastatic  Stage IV 54 12 
 
 
Detection rates for mutant KRAS exoDNA in a control cohort of 136 prospective samples that did 
not undergo capture enrichment (total exosomes) taken during active chemotherapeutic 
intervention was 32.7% (17/52), 50% (15/30), and 51.8% (28/54) in resectable, locally advanced, 
and metastatic disease, respectively as defined by American Joint Committee on Cancer 
guidelines (Figure 24). In 37 samples that underwent exosome capture as previously described, 
our mutation detection rate increased to 70.6% (12/17), 71.4% (5/7), and 76.9% (10/13) in 
resectable, locally advanced, and metastatic disease, respectively. Of note, these  




Figure 24 exoDNA KRAS mutant detection in circulation 
(A) Percent of patients with detectable mutant KRAS in exoDNA among those patient samples 
that did and did not undergo capture enrichment. When comparing the percentages of patients 
with detectable KRAS in the pulldown-cohort versus the total exosome cohort, the pulldown-cohort 
consistently detects KRAS in a higher proportion of patients across stages. This increase in call-
rate was statistically significant in resectable patients (P = 0.024) where pulldown samples were 
4.11 (95% CI: 1.14–17.19) more likely to have KRAS detected. (B) KRAS mutant allele frequency 
(MAF) comparisons of captured exosomes versus total exosomes, there was a statistically 
significant difference showing increased KRAS MAFs from the captured exosomes for resectable 
and metastatic patients (P = 0.003 and 0.015, respectively, using one-sided Wilcoxon Rank Sum 
tests). 
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detection rates reach the theoretical upper limit of detection of our ddPCR multiplex assay which 
can detect up to 80% of known KRAS mutations found in PDAC (37).  This suggests that most 
patient undergoing therapy have tumor-derived material in circulation that is typically 
overwhelmed by non-neoplastic tissue derived exosomes. Harvested exoDNA from both 
protocols yielded an average of 19.17ng (0.11-125.72ng) and 24.13ng (0.12-636.00ng) for 
captured exosomes and total exosomes, respectively. Overall positive call rate among all 
combined patients is associated with the pulldown cohort (p-val = 0.002) where a pulldown 
sample is 3.28 (95% CI: 1.41 - 8.19) times more likely to have KRAS detected. Importantly, 
exosome capture not only increases the proportion of cases with detectable mutant alleles, but 
also leads to a statistically significant increase in KRAS MAF within each category, serving as a 
surrogate for tumor enrichment capability (Figure 24B).  
 
Enriched cancer-specific exosomal cargo is amenable to comprehensive molecular 
profiling by NGS 
A metastatic PDAC patient who underwent prior tumor resection, and subsequently developed 
liver metastasis underwent liquid biopsies for exosome isolation.  The emergence of metastasis 
corresponded with clinically detectable resistance to a Rucaparib (PARP1 inhibitor) clinical trial 
which the patient was stratified into due a somatic frameshift BRCA2 (L583*) mutation with 
associated loss of heterozygosity. Plasma-derived exosomes were isolated and profiled for 
KRAS mutant detection revealing an increase in KRAS mutant burden during disease 
progression (Figure 25). In an on-treatment blood draw where no exoDNA mutant KRAS was 
detected based on ddPCR, we subsequently attempted exoDNA enrichment resulting in an 
increase in mutational KRAS allelic fraction from 0% to 3.2%. More importantly, the amount of 
DNA material was sufficient for subsequent NGS using a molecular barcoding approach. This 
resulted in the detection of the known driver mutations that were present in the patient’s original 
primary tumor, and subsequently detected in the metastatic liver tissue, including mutations in 
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KRAS, TP53, and BRCA2. Notably a secondary mutation in BRCA2 was also detected in liquid 
biopsies which was not present in the original primary tissue, likely arising during PARP inhibitor 
therapy. This mutation resided immediately prior to exon 10 where the BRCA2 (L583*) mutation 
was present allowing for the entire exon to be spliced out and leading to transcription of a full 
mRNA molecule. Tumor exosomal DNA enrichment thus allowed us to detect this putative 
mechanism of resistance to PARP inhibitor, underscoring the utility of liquid biopsies in facilitating 
therapeutic stratification.  
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 Figure 25 Detection of cancer mutations in capture exosomes through molecular 
barcodes 
(A) Clinical course of a pancreatic ductal adenocarcinoma patient who underwent prior 
pancreatic tumor resection, and subsequently progressed while on Parp-1 inhibitor therapy. 
ExoDNA enrichment led to capture of tumor derived material which was not previously 
detectable. (B) Relevant mutations found in the metastatic tissue and liquid biopsies 6 months 
(lbx_02) and 9 months (lbx_03) after tissue biopsy. Of note is the presence of a 
stopgain BRCAmutation (L583*) that was correlated to her prolonged response to PARP1 
inhibitor therapy. (C) A subsequent mechanism of resistance was detected in the liquid biopsies 
and confirmed in the tissue in the form of a BRCA2 splice site variant which splices out the 
aberrant stopgain mutation. SLD sum of the largest dimension; exoDNA MAF represent 
the KRAS mutant allele fraction. ABR, abraxane (nab-paclitaxel); CIS, cisplatin; GEM, 
gemcitabine. 
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Discussion 
We have performed proteomic profiling of exosomes isolated from a panel of PDAC cells in order 
to identify a candidate list of cancer-specific surface exosomal proteins (the PDAC exosomal 
“surfaceome”). We validated the cancer specificity of these exosomal proteins by performing the 
same proteomic profiling in non-neoplastic pancreatic cell types, and examining which candidate 
proteins were differentially and preferentially expressed by the collective PDAC exosomal 
“surfacesome”. The resultant PDAC-exosome specific markers can be exploited using an 
immunocapture assay for enrichment of tumor specific material in liquid biopsies. This allows for 
subsequent molecular analysis of tumor material with implications for early detection, longitudinal 
disease monitoring (especially in low tumor volume settings), and therapeutic stratification during 
targeted therapy.  
 
Since it is possible that the exosome “surfaceome” may evolve throughout disease progression 
and may, in fact, be a product of the intrinsic heterogeneity found in PDAC, we opted to pursue 
a multiplexed panel of antibodies against six candidate biomarkers for validation. These included 
CLDN4, EPCAM, CD151, LGALS3BP, HIST2H2BE and HIST2H2BF. As evidenced by our data, 
these biomarkers appear to greatly enhance not only the fraction of patients at each PDAC stage 
with detectable mutant molecules, but also the mutant allelic fraction per se at each stage, 
suggesting enrichment for the tumor-derived nucleic acid component. The latter has direct 
implications for downstream molecular assessment using NGS that can be pursued in liquid 
biopsy samples.   
 
Mechanisms of DNA packaging within exosomes remain largely unknown as opposed to the 
apoptotic/necrotic pathways that are mostly recognized as sources of ctDNA in circulation. In the 
nucleus, histones are essential for chromatin structure and play a crucial role during gene 
transcription and silencing. Interestingly, histones have also been found outside the nucleus, in 
the cytosol, mitochondria and cell membrane (193). Extrachromosomal Histone-H2B has been 
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identified as a cytosolic DNA sensor for aberrant self and non-self double-stranded DNA, which 
mediates an innate immune response and co-localizes within the mitochondrial membrane (194, 
195). Upon detection of cytosolic DNA, H2B has been described to partially associate with 
mitochondria and co-localize with the late endosome marker CD63 (93). Both mitochondria and 
endosomes are known to generate multivesicular bodies that can fuse with the cell membrane 
and generate exosomes (196). Therefore the relative enrichment of H2B within the exosome 
compartment of cancer cells suggests that this protein may be interacting with mutant DNA that 
originated in the nucleus and which subsequently becomes packaged within exosomes for 
transport.  
 
Not unexpectedly, the other candidate exosomal “surfaceome” proteins identified in our analysis 
have been independently implicated in cancer initiation and progression of PDAC. For example, 
the extracellular matrix glycoprotein LGALS3BP is overexpressed by neoplastic cells with a role 
in promoting cell viability, migration and metastasis, resulting in its role as a potential biomarker 
associated with prognosis and response to therapy (196, 197). Other identified biomarkers such 
as the tetraspanin family member CD151 have also been implicated in cancer initiation and 
metastasis; in fact, exosomal CD151 per se has previously been shown to facilitate metastasis 
through induction of epithelial to mesenchymal transition in PDAC cell lines (92). The family of 
claudin proteins is involved in the formation of tight junctions, with overexpression of CLDN4 
previously described in the context of PDAC (198). Notably, this overexpression was present in 
both human archival material and genetically engineered mouse models at the stage of PDAC 
precursor lesions (pancreatic intraepithelial neoplasia (PanIN)), with implications for early 
detection (199). Finally, expression of epithelial markers in circulation has been best 
characterized in the context of circulating tumor cells (CTCs). Specifically, the use of EPCAM to 
isolate and quantify CTCs has led to FDA approved prognostic tests in colorectal, breast, and 
prostate cancers (200). As the majority of content in circulation is derived from blood components 
such as peripheral blood mononuclear cells (PBMCs), the presence of circulating material 
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expressing epithelial proteins such as EPCAM are postulated to represent tumor-derived origins. 
This is further supported by our own data, which suggest that EPCAM in circulation may 
represent a cancer specific exosomal biomarker (201).  
 
Previous work has demonstrated the utility of the biomarker GPC1 as a highly sensitive and 
specific exosomal biomarker for detection of PDAC (138). While our proteomics data does 
confirm that GPC1 is expressed on the PDAC-derived exosomal “surfaceome”, upon 
incorporation of public extracellular vesicle databases, this protein appears to be also enriched 
in exosomes originating from normal tissues. Further, our experimental data confirms the 
presence of GPC1 in non-neoplastic cell lines including CAF19 and SC2, while not being 
expressed within the exosomes of three representative PDAC cell lines following attempted 
validation using multiple commercially available antibodies. A recent study by Yang et al also 
found that GPC1 as a single exosome marker was not optimal in PDAC plasma samples, 
although it could potentially be used as a component of a multi-analyte panel (192). Thus, the 
significance of GPC1 in PDAC liquid biopsies will require future clarification.   
 
Among limitations of this study are the fact that we were unable to obtain matched captured and 
non-captured total exosome samples from the same patient due to the volumes of plasma 
required to pursue both protocols. The purpose of utilizing these volumes (~11.7ml of plasma) 
was to have sufficient nucleic acid material for downstream NGS analysis. Additionally, our 
relatively small sample size which underwent exosome capture may limit the generalization of 
our conclusions and would require further validation in larger cohorts. It would also be prudent to 
perform this analysis on a cohort of healthy controls in order to effectively validate the specificity 
of our cancer derived exosome capture approach for KRAS mutation detection. Finally, it is 
important to note the feasibility of implementing such a protocol in the clinics. Whereas plasma 
processing and DNA isolation for ctDNA can be performed within a day, the need to isolate 
exosomes using a bead immunocapture based approach followed by DNA isolation would 
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require four days in addition to the required infrastructure needed for ultracentrifugation. Although 
it is not a significant processing time difference, new exosome isolation approaches are being 
developed to decrease cost and increase efficiency of specific exosome capture without the need 
for ultracentrifugation. This includes the use of antibody coated chips and microfluidic based 
approaches which can capture specific exosome populations of interest (202, 203) 
 
The need to enrich for tumor derived material in circulation is underlined by the difficulties in 
detecting rare circulating mutant molecules in a heterogeneous milieu that is typically 
overwhelmed by non-neoplastic tissue derived DNA. This is particularly compounded in the 
context of patients undergoing therapy where mutant DNA might be at levels that are 
undetectable with conventional ultra-sensitive digital PCR techniques. The ability to detect latent 
mutant molecules has implications in uncovering emerging mechanisms of resistance or 
vulnerability nodes before these become clinically evident, thus allowing for more effective 
therapeutic stratification. As typical circulating biomarkers such as ctDNA are not amenable to 
enrichment methodologies, we present exosomes as a viable alternative to capture tumor 
specific material. This can come in the form of not only DNA, but also mRNA and proteins that 
are sourced from the originating tumor cell. Indeed, we have demonstrated how a tumor 
enrichment platform can lead to detectable tumor material in those patients initially thought to be 
free of circulating mutant molecules. But more importantly, specific tumor exosome enrichment 
leads to an augmentation of mutant genomic equivalents that are subsequently amenable to 
NGS. For example, in our cohort of resectable patients, 44% of patient samples from total 
exosomes had sufficient quantity and quality of DNA to undergo downstream molecular 
barcoding (as defined by >1% KRAS mutant AF and >1ng of isolated DNA), compared to 67% 
of patient samples that were subject to exosome capture. This enrichment then permits 
elucidation of emerging mechanisms of resistance, such as a secondary BRCA2 mutation that 
reverts PARP sensitivity, as we have demonstrated in our study.  
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Chapter 7 – Discussion and Future Directions  
 
 
Throughout this work, we have demonstrated that both circulating tumor DNA and exosomal 
derived DNA are amendable to detection through digital PCR and NGS based methods. 
Exosomes provide an interesting alternative and complementary approach to conventional liquid 
biopsy compartments such as cfDNA as the surface composition of these extracellular vesicles 
can give us information of the type of cell where they came from while their content can give us 
insight into the functional state of that cell of origin. Although much work has been done 
describing the cargo of these microvesicles including proteins and RNA, the existence of DNA 
and how it becomes packaged within the vesicles still remains an area of debate. As opposed to 
ctDNA which is a product of rapid cell turnover following apoptosis and necrosis, packaging of 
exoDNA would need to occur in viable cells through unknown functional mechanisms. Based on 
our observations of the presence of histone components in our exosome proteomics, we had 
hypothesized that these were byproducts of extrachromosomal DNA. Histones in themselves 
would then serve as cytosolic DNA sensors for aberrant self and non-self double-stranded DNA, 
which can co-localize with CD63, a known exosomal marker (93). A related mechanism to 
exosomal DNA packaging was more recently elucidated whereby cells utilize exosomes as a 
means to eliminate harmful cytosolic DNA and thus preventing activation of DNA damage 
response pathways (204). Specifically, Takahash, et al., found that inhibiting exosome secretion 
of cells resulted in an increase of cytosolic DNA which was recognized by STING and provoked 
a reactive oxygen species dependent DNA damage response. This effect was rescued through 
overexpression of cytoplasmic DNases which inhibited STING activity. These results suggest 
that exosomes play an important role in maintaining cellular homeostasis by removing aberrant 
cytoplasmic DNA. Based on this data, one can then hypothesize that exosomes in general may 
contain an enriched pool of aberrant or mutated DNA from cells, suggesting that they may 
represent an enriched source of tumor derived material in circulation when compared to cell-free 
DNA. This seems to be supported by our work presented in Chapter 3 where presence of KRAS 
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mutations was more readily detectable in exosomes compared to cfDNA of matched patient 
samples. Additionally, our data in Chapter 4 further demonstrates that in addition to higher 
sensitivity of detection of KRAS in circulation, these mutant molecules contained within 
exosomes are of higher variant allele frequency when compared to matched ctDNA. Although 
this data is of course correlative, it would further support the role of exoDNA as another putative 
biomarker amongst liquid biopsies.  
The role of liquid biopsies as a field lies in its potential for early detection, prognostication, tumor 
monitoring, and therapy guidance. Among this, early detection remains the greatest endeavor, 
particularly in pancreatic cancer, where identification of those patients at high risk of developing 
or having localized disease can lead to potential curative surgical resection, which would result 
in a significant impact on survival in this disease. Unfortunately, several issues must be 
considered in developing an early detection assay such as the one proposed for liquid biopsies. 
These include: 1. Sensitivity and specificity, 2. Organ specificity, 3. A numbers problem, 4. 
Lethality problems, 5. Lead time problem.  
In regards to sensitivity and specificity, we’ve demonstrated in Chapter 3 that a significant hurdle 
in regards to specificity is that apparently healthy individuals can carry known “driver” mutant 
molecules in circulation possibly originating from non-clinically relevant lesions. Thus, the current 
strategy used in this work of detecting a single point mutation would not be optimal in the setting 
of an early detection screening methodology as a significant number of false positives would 
arise. One potential solution for this would be to determine the utility of a panel of gene mutations 
or genomic signature that may predict the presence of cancer. In the context of PDAC for 
example, this can involve using a panel of the top 4 mutated genes, KRAS, TP53, SMAD4, and 
CDKN2A. Detection of 3 or more of these as related to potential driver status may thus increase 
the specificity of such an assay. Commercial efforts are currently underway to perform such 
analysis on large sets of patients. Most recently, GRAIL has raised more than $950 million to 
recruit 120,000 women to perform liquid biopsies at the time of mammography. Their goal is to 
develop a signature related to breast cancer that involves gene panel sequencing, whole genome 
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sequencing, and methylation status through bisulfite genomic sequencing. If successful, studies 
such as these would greatly advance the field of liquid biopsies, as it would support further clinical 
utility of these biomarkers, unfortunately, performing such studies will not be feasible among 
other cancer types. Additionally, even if successful, implementing such assays in general 
populations may not be possible due to cost and suboptimal sensitivity/specificity. Thus, at least 
in the case of pancreatic cancer, high risk populations would be best stratified for such studies 
including those with a family history of cancer, genetic predisposition syndromes (e.g. BRCA2 
mutant status), chronic pancreatitis, smokers, and new onset diabetes.   
In the context of organ specificity, utilizing KRAS as an early detection marker will not yield much 
information considering it is prevalent in many other cancers including lung, colon, and 
pancreatic. Again, the GRAIL study is attempting to overcome this issue by finding a specific 
signature correlated to breast cancer through their sequencing strategy. But development of such 
tools in other cancers may again not be possible due to cost.  
In the numbers problem, it is important to consider that hundreds, maybe thousands of 
biomarkers exist today, so how do we go about validating them? We cannot perform $1 billion 
experiments every time a new attractive biomarker shows up, so what would be the best strategy 
to select those most likely to become effective and through which trials? Additionally, even with 
ctDNA, there are many methodologies available today to profile this liquid biopsy compartment, 
including digital PCR, whole genome sequencing, and numerous gene panels coupled with 
molecular barcodes with undisclosed targeting strategies. 
In regards to the lethality problem, it’s of course important to note that even if we can detect 
cancer early in general, not all cancers will be lethal. An example being that of prostate cancer, 
where most men would die with prostate cancer but not of prostate cancer. But even in the case 
of studies such as those by GRAIL, not all ductal carcinomas in situ (DCIS) will develop an 
invasive component. In that case, how can we best stratify those patients that are likely to benefit 
most from surgical resection in order to circumvent morbidity and costs.  
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Finally, by lead time problem we mean, what is the difference in time between a positive test on 
a liquid biopsy and a positive result on imaging such as CT or mammography. In the context of 
breast cancer, if this is just 1-2 weeks, then is there any real benefit to this new biomarker? In 
Chapter 4 we describe an average lead time of 50 days, but considering the rapid clinical 
deterioration of pancreatic cancer, can a biomarker such as this be relevant and result in 
significant survival benefits? Several studies have attempted to report clinically relevant lead 
times such as Tie et al., who describe a lead time to radiological recurrence of colon cancer of 5 
months compared to CEA following resection, and Chaudhuri, et al., who describe a lead time of 
5.2 months for localized lung cancer which they attribute to the presence of minimally residual 
disease (149, 205). Regardless of these findings, a prospective randomized trial validating the 
utility of these lead times would need to be conducted. 
Ultimately, it is the personal view of this author, that liquid biopsies in the form of circulating tumor 
DNA or exosomal DNA are not optimal for their use in early detection. The cost and specificity 
needed to implement such assays today are likely not possible and would most likely be better 
suited for the proteomic field where biosample requirements are not as strenuous.  
It is not to say that liquid biopsies have no use at all. It is the opinion of the author that such 
assays are better suited for tumor monitoring and therapy selection. Yet certain caveats remain 
regarding the use of liquid biopsies for these purposes today. As many studies on the clinical 
significance of circulating nucleic acids have been retrospective in nature, few evidence exists of 
the utility of such assays in a randomized prospective clinical trial setting. While the current data 
in this dissertation may suggest clinical validity in context of prediction when certain biomarker 
thresholds have been met, we believe that one of the greatest barriers to clinical implementation 
will rely on establishing clinical utility through prospective trials. Although it is important to note 
the requirements to establish pre-analytical and analytical validity, several methodologies and 
assays have been able to establish this, but still with a lack of evidence of clinical utility. 
Parameters of pre-analytic and analytical validity rely on the reproducibility of results. This begins 
to incorporate variability related to time of draws, needles and blood tubes used, time to 
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processing, and other standard operating procedures of the blood processing and assay itself. 
Within our own studies we attempt to use only acid citrate dextrose (ACD) tubes for plasma 
collection and process blood within one hour of time of collection, but the latter is not always 
feasible, particularly outside of the clinical trial realm. This requires clinical studies infrastructure 
which include a clinical coordinator and respective personnel. Next clinical, validation must be 
established through Clinical Laboratory Improvement Amendments (CLIA) certification in order 
to establish a quality standard of accuracy, reliability, and timeliness of results. Again this has 
been established in certain scenarios for ctDNA, but the current nature of the isolation and 
processing of exosomes would likely make it difficult for such SOPs and validation to become 
viable. Due to the complexity and user variability involved in exosome isolation through 
ultracentrifugation, the exosome field may find more success with microfluidic based methods 
which can become more standardized. Similar to the immune-capture approach presented in 
Chapter 6, one can envision a microfluidic chip coated with antibodies of interest similar to 
methodologies established for circulating tumor cells (206). In regards to clinical utility, in this 
current study, we attempt to provide retrospective evidence for disease monitoring in the context 
of pancreatic cancer, but we envision establishing clinical utility through a prospective clinical 
trial with the same intended use. This could involve monitoring of metastatic pancreatic cancer 
patients through serial liquid biopsies, where detection of exoDNA MAF >1% would stratify 
patients into receiving early follow-up imaging for detection of progression and a change to 
second-line chemotherapy. 
In summary, as an emerging biomarker in the field of solid cancers, the potential of liquid biopsies 
as being a minimally invasive means of prognostication and tumor monitoring can bring about 
significant survival benefits. These benefits would likely be better leveraged when using 
complementary biomarkers such as presented in this work including standard clinical biomarkers 
(CA19-9) as well as liquid biopsy sources of nucleic acid material (cfDNA and exosomes).  
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